

Evangelos Terpos

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/63699/evangelos-terpos-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

869
papers

26,447
citations

78
h-index

142
g-index

943
ext. papers

32,211
ext. citations

4.2
avg. IF

7.03
L-index

#	Paper	IF	Citations
869	Booster BNT162b2 Optimizes SARS-CoV-2 Humoral Response in Myeloma Patients; the Negative Effect of anti-BCMA therapy.. <i>Blood</i> , 2022 ,	2.2	6
868	Third Dose of the BNT162b2 Vaccine Results in Very High Levels of Neutralizing Antibodies Against SARS-CoV-2; Results of a Prospective Study in 150 Health Professionals in Greece.. <i>American Journal of Hematology</i> , 2022 ,	7.1	4
867	Persisting Endothelial Cell Activation and Hypercoagulability after COVID-19 RecoveryThe Prospective Observational ROADMAP-Post COVID-19 Study. <i>Hemato</i> , 2022 , 3, 111-121	0.2	1
866	Comparison of Neutralizing Antibody Responses at 6 Months Post Vaccination with BNT162b2 and AZD1222.. <i>Biomedicines</i> , 2022 , 10,	4.8	3
865	Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group.. <i>Lancet Haematology,the</i> , 2022 , 9, e143-e161	14.6	6
864	Sustained but Declining Humoral Immunity Against SARS-CoV-2 at 9 Months Postvaccination With BNT162b2: A Prospective Evaluation in 309 Healthy Individuals.. <i>HemaSphere</i> , 2022 , 6, e677	0.3	4
863	Osteocytes and bone tumor niche 2022 , 171-178		
862	Recent therapeutic approaches in myeloma 2022 , 1019-1029		
861	An overview of treatment options for patients with relapsed/refractory multiple myeloma and renal impairment.. <i>Therapeutic Advances in Hematology</i> , 2022 , 13, 20406207221088458	5.7	
860	Patients With Autoimmune Thyroiditis Present Similar Immunological Response to COVID-19 BNT162b2 mRNA Vaccine With Healthy Subjects, While Vaccination May Affect Thyroid Function: A Clinical Study.. <i>Frontiers in Endocrinology</i> , 2022 , 13, 840668	5.7	1
859	Treatment Resistance Risk in Patients with Newly Diagnosed Multiple Myeloma Is Associated with Blood Hypercoagulability: The ROADMAP-MM Study. <i>Hemato</i> , 2022 , 3, 188-203	0.2	
858	The COMPASS-COVID-19-ICU Study: Identification of Factors to Predict the Risk of Intubation and Mortality in Patients with Severe COVID-19. <i>Hemato</i> , 2022 , 3, 204-218	0.2	
857	Carfilzomib 56 mg/m twice-weekly in combination with dexamethasone and daratumumab (KdD) versus daratumumab in combination with bortezomib and dexamethasone (DVd): a matching-adjusted indirect treatment comparison.. <i>Leukemia and Lymphoma</i> , 2022 , 1-10	1.9	
856	Comparison of MRI Features of Fat Fraction and ADC for Early Treatment Response Assessment in Participants with Multiple Myeloma.. <i>Radiology</i> , 2022 , 211388	20.5	0
855	Oxidative stress and endogenous DNA damage in blood mononuclear cells may predict anti-SARS-CoV-2 antibody titers after vaccination in older adults.. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2022 , 166393	6.9	1
854	Adverse effects of COVID-19 mRNA vaccines: the spike hypothesis.. <i>Trends in Molecular Medicine</i> , 2022 ,	11.5	14
853	Pomalidomide- and dexamethasone-based regimens in the treatment of refractory/relapsed multiple myeloma.. <i>Therapeutic Advances in Hematology</i> , 2022 , 13, 20406207221090089	5.7	

852	Newly Diagnosed Multiple Myeloma Patients with Skeletal-Related Events and Abnormal MRI Pattern Have Poor Survival Outcomes: A Prospective Study on 370 Patients. <i>Journal of Clinical Medicine</i> , 2022 , 11, 3088	5.1	0
851	SARS-CoV-2 Neutralizing Antibodies Kinetics Postvaccination in Cancer Patients under Treatment with Immune Checkpoint Inhibition. <i>Cancers</i> , 2022 , 14, 2796	6.6	2
850	Daratumumab Improves Bone Turnover in Relapsed/Refractory Multiple Myeloma; Phase 2 Study REBUILD <i>Cancers</i> , 2022 , 14, 2768	6.6	0
849	Consumption of Fruits, Vegetables and Bladder Cancer Risk: A Systematic Review and Meta-Analysis of Prospective Cohort Studies. <i>Nutrition and Cancer</i> , 2021 , 1-14	2.8	0
848	Kinetics of anti-SARS-CoV-2 neutralizing antibodies development after BNT162b2 vaccination in patients with amyloidosis and the impact of therapy. <i>American Journal of Hematology</i> , 2021 , 97, E27	7.1	2
847	Circulating Tumor Cells (CTCs) in Smoldering and Active Multiple Myeloma (MM): Mechanism of Egression, Clinical Significance and Therapeutic Endpoints. <i>Blood</i> , 2021 , 138, 76-76	2.2	2
846	Kinetics of Anti-Sars-Cov-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers. <i>Blood</i> , 2021 , 138, 4202-4202	2.2	
845	Patients with Multiple Myeloma and Prior COVID-19 Have Superior Antibody Responses Against Sars-Cov-2 Compared with Fully Vaccinated Myeloma Patients with the BNT162b2 Vaccine. <i>Blood</i> , 2021 , 138, 3802-3802	2.2	
844	Single Cell Analysis of MYD88 L265P and MYD88 WT Waldenström Macroglobulinemia Patients. <i>Blood</i> , 2021 , 138, 1599-1599	2.2	
843	Impact of Daratumumab-Containing Induction on Stem Cell Mobilization and Collection, Engraftment and Hospitalization Parameters Among Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation. <i>Blood</i> , 2021 , 138, 3886-3886	2.2	0
842	Evaluation of Efficacy and Immune Modulation Associated with the Addition of IMiDs to Daratumumab Backbone in Patients Refractory to Both Drug Classes. <i>Blood</i> , 2021 , 138, 1668-1668	2.2	1
841	Antibody Response after Vaccination for Sars-Cov-2 in Patients with AL Amyloidosis and the Impact of Therapy. <i>Blood</i> , 2021 , 138, 3799-3799	2.2	
840	The INSURE Study (INSIGHT MM, UVEA-IXA, REMIX): A Pooled Analysis of Relapsed/Refractory Multiple Myeloma (RRMM) Patients (pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) in Routine Clinical Practice. <i>Blood</i> , 2021 , 138, 2701-2701	2.2	
839	Patients with Multiple Myeloma on Anti-CD38 or Anti-BCMA Based Regimens and Patients with Waldenström's Macroglobulinemia Under Rituximab or BTK Inhibitors Have a Poor Humoral Response Following COVID-19 Vaccination. <i>Blood</i> , 2021 , 138, 3791-3791	2.2	
838	Safety and Efficacy of Daratumumab with Ixazomib and Dexamethasone in Patients with One Prior Lenalidomide-Based Regimen: Outcomes of the Phase 2 Daria Study. <i>Blood</i> , 2021 , 138, 2737-2737	2.2	0
837	Impact of Daratumumab Monotherapy on Bone Metabolism Parameters in Patients with Relapsed and/or Refractory Multiple Myeloma Who Have Received at Least Two Prior Lines of Therapy Including Lenalidomide and a Proteasome Inhibitor: Outcomes of the Phase 2 Rebuild Study. <i>Blood</i> , 2021 , 138, 1670-1670	2.2	
836	Prospective Assessment of Biomarkers of Hypercoagulability in Oncological Patients and Healthcare Workers Following Vaccination Against Sars-Cov-2 with the mRNA Vaccine. the Roadmap-COVID-19-Vaccin Study. <i>Blood</i> , 2021 , 138, 3207-3207	2.2	
835	A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination with Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2021 , 138, 2736-2736	2.2	0

834	Safety of Daratumumab Combined with Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Patients with Multiple Myeloma Presenting with Extramedullary Disease during the COVID-19 Pandemic. <i>Blood</i> , 2021 , 138, 1657-1657	2.2	
833	Poor Neutralizing Antibody Responses in Patients with CLL, NHL and HL after Vaccination Against Sars-Cov-2; A Prospective Study in 132 Patients. <i>Blood</i> , 2021 , 138, 3752-3752	2.2	
832	The Compass-COVID19-ICU Study: Identification of Factors to Predict the Risk of Intubation and Mortality in Patients with Severe COVID-19. <i>Blood</i> , 2021 , 138, 2121-2121	2.2	
831	Changing Patterns of Symptomatic Myeloma after the Implementation of the 2014 IMWG Diagnostic Criteria and Reduced Early Mortality. <i>Blood</i> , 2021 , 138, 1636-1636	2.2	0
830	Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14 Months After SARS-CoV-2 Infection.. <i>Frontiers in Immunology</i> , 2021 , 12, 793953	8.4	6
829	Efficacy and Safety of Daratumumab with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment or on Dialysis: Final Analysis of the Phase 2 Dare Study. <i>Blood</i> , 2021 , 138, 2729-2729	2.2	0
828	tRNA Derivatives in Multiple Myeloma: Investigation of the Potential Value of a tRNA-Derived Molecular Signature.. <i>Biomedicines</i> , 2021 , 9,	4.8	2
827	Elucidating Carfilzomib's Induced Cardiotoxicity in an In Vivo Model of Aging: Prophylactic Potential of Metformin. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	2
826	Late-onset hematological complications post COVID-19: An emerging medical problem for the hematologist. <i>American Journal of Hematology</i> , 2021 , 97, 119	7.1	7
825	Robust Neutralizing Antibody Responses 6 Months Post Vaccination with BNT162b2: A Prospective Study in 308 Healthy Individuals. <i>Life</i> , 2021 , 11,	3	13
824	Immunological Response to COVID-19 Vaccination in Ovarian Cancer Patients Receiving PARP Inhibitors. <i>Vaccines</i> , 2021 , 9,	5.3	3
823	Blood Transcriptomes of Anti-SARS-CoV-2 Antibody-Positive Healthy Individuals Who Experienced Asymptomatic Clinical Infection. <i>Frontiers in Immunology</i> , 2021 , 12, 746203	8.4	2
822	Treatment with abiraterone or enzalutamide does not impair immunological response to COVID-19 vaccination in prostate cancer patients. <i>Prostate Cancer and Prostatic Diseases</i> , 2021 ,	6.2	3
821	Distinct neutralization profile of spike variants by antibodies induced upon SARS-CoV-2 infection or vaccination. <i>American Journal of Hematology</i> , 2021 , 97, E3	7.1	6
820	COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network. <i>Lancet Haematology</i> , 2021 , 8, e934-e946	14.6	9
819	miRNA-seq and clinical evaluation in multiple myeloma: miR-181a overexpression predicts short-term disease progression and poor post-treatment outcome. <i>British Journal of Cancer</i> , 2021 ,	8.7	4
818	Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. <i>HemaSphere</i> , 2021 , 5, e528	0.3	19
817	Controversies in the use of new bone-modifying therapies in multiple myeloma. <i>British Journal of Haematology</i> , 2021 , 193, 1034-1043	4.5	6

816	Carfilzomib Improves Bone Metabolism in Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results of the CarMMa Study. <i>Cancers</i> , 2021 , 13,	6.6	3
815	SARS-CoV-2 Infection Is Asymptomatic in Nearly Half of Adults with Robust Anti-Spike Protein Receptor-Binding Domain Antibody Response. <i>Vaccines</i> , 2021 , 9,	5.3	6
814	Accurate SARS-CoV-2 seroprevalence surveys require robust multi-antigen assays. <i>Scientific Reports</i> , 2021 , 11, 6614	4.9	6
813	Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group. <i>Lancet Oncology, The</i> , 2021 , 22, e119-e130	21.7	33
812	Recovery of Innate Immune Cells and Persisting Alterations in Adaptive Immunity in the Peripheral Blood of Convalescent Plasma Donors at Eight Months Post SARS-CoV-2 Infection. <i>Microorganisms</i> , 2021 , 9,	4.9	7
811	Whole-Body Low-Dose CT in Multiple Myeloma: Diagnostic Value of Appendicular Medullary Patterns of Attenuation. <i>American Journal of Roentgenology</i> , 2021 , 216, 742-751	5.4	3
810	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. <i>Lancet Oncology, The</i> , 2021 , 22, e105-e118	21.7	32
809	Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2021 , 32, 309-322	10.3	69
808	Integrin expression in correlation to clinicopathological features and prognosis of prostate cancer: A systematic review and meta-analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021 , 39, 221-232	2.8	0
807	A Phase II Study on the Use of Convalescent Plasma for the Treatment of Severe COVID-19- A Propensity Score-Matched Control Analysis. <i>Microorganisms</i> , 2021 , 9,	4.9	8
806	European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma. <i>Haematologica</i> , 2021 , 106, 2054-2065	6.6	8
805	Age-dependent and gender-dependent antibody responses against SARS-CoV-2 in health workers and octogenarians after vaccination with the BNT162b2 mRNA vaccine. <i>American Journal of Hematology</i> , 2021 , 96, E257-E259	7.1	61
804	Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose. <i>Blood</i> , 2021 , 137, 3674-3676	2.2	80
803	Pomalidomide Plus Low-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Results of the Real-World "POWERFUL" Study. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	1
802	The Role of Marrow Microenvironment in the Growth and Development of Malignant Plasma Cells in Multiple Myeloma. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	11
801	Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US. <i>Annals of Hematology</i> , 2021 , 100, 2325-2337	3	4
800	Low titers of SARS-CoV-2 neutralizing antibodies after first vaccination dose in cancer patients receiving checkpoint inhibitors. <i>Journal of Hematology and Oncology</i> , 2021 , 14, 86	22.4	19
799	Clinical Application of a New SARS-CoV-2 Antigen Detection Kit (Colloidal Gold) in the Detection of COVID-19. <i>Diagnostics</i> , 2021 , 11,	3.8	5

798	Covid-19 vaccination in patients with multiple myeloma: Focus on immune response. <i>American Journal of Hematology</i> , 2021 , 96, 896-900	7.1	4
797	Identification of Very Low-Risk Subgroups of Patients with Primary Mediastinal Large B-Cell Lymphoma Treated with R-CHOP. <i>Oncologist</i> , 2021 , 26, 597-609	5.7	5
796	Comparison of neutralizing antibody responses against SARS-CoV-2 in healthy volunteers who received the BNT162b2 mRNA or the AZD1222 vaccine: Should the second AZD1222 vaccine dose be given earlier?. <i>American Journal of Hematology</i> , 2021 , 96, E321-E324	7.1	11
795	Overweight/Obesity and Monoclonal Gammopathy of Undetermined Significance. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021 , 21, 361-367	2	2
794	Real-World Treatment of Patients With Relapsed/Refractory Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021 , 21, 379-385	2	3
793	Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , 2021 , 22, 801-812	21.7	35
792	The Spectrum of Ocular Manifestations in Patients with Waldenström's Macroglobulinemia. <i>Ocular Immunology and Inflammation</i> , 2021 , 1-10	2.8	2
791	A Molecular Signature of Circulating MicroRNA Can Predict Osteolytic Bone Disease in Multiple Myeloma. <i>Cancers</i> , 2021 , 13,	6.6	5
790	Epidemiology and organ specific sequelae of post-acute COVID19: A narrative review. <i>Journal of Infection</i> , 2021 , 83, 1-16	18.9	38
789	Next generation flow cytometry for MRD detection in patients with AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2021 , 28, 19-23	2.7	15
788	Timing and impact of a deep response in the outcome of patients with systemic light chain (AL) amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2021 , 28, 3-11	2.7	6
787	Emerging treatment strategies for COVID-19 infection. <i>Clinical and Experimental Medicine</i> , 2021 , 21, 167-179	17.9	81
786	A proposed index of diffuse bone marrow [18F]-FDG uptake and PET skeletal patterns correlate with myeloma prognostic markers, plasma cell morphology, and response to therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021 , 48, 1487-1497	8.8	0
785	Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network. <i>Leukemia</i> , 2021 , 35, 31-44	10.7	39
784	Daratumumab-based therapy for patients with monoclonal gammopathy of renal significance. <i>British Journal of Haematology</i> , 2021 , 193, 113-118	4.5	5
783	Screening for Gaucher disease among patients with plasma cell dyscrasias. <i>Leukemia and Lymphoma</i> , 2021 , 62, 761-763	1.9	0
782	Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications. <i>Journal of Biomedical Science</i> , 2021 , 28, 9	13.3	52
781	TP53 mutations determined by targeted NGS in breast cancer: a case-control study. <i>Oncotarget</i> , 2021 , 12, 2206-2214	3.3	2

780 Therapy of Myeloma Bone Disease **2021**, 111-137

779 Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life. *Blood Cancer Journal*, **2021**, 11, 40 7 11

778 Denosumab compared with zoledronic acid on PFS in multiple myeloma: exploratory results of an international phase 3 study. *Blood Advances*, **2021**, 5, 725-736 7.8 7

777 Positron emission tomography after response to rituximab-CHOP in primary mediastinal large B-cell lymphoma: impact on outcomes and radiotherapy strategies. *Annals of Hematology*, **2021**, 100, 2279-2292 3 5

776 Carfilzomib-induced endothelial dysfunction, recovery of proteasome activity, and prediction of cardiovascular complications: a prospective study. *Leukemia*, **2021**, 35, 1418-1427 10.7 3

775 Continuing Cancer Therapy through the Pandemic While Protecting Our Patients: Results of the Implementation of Preventive Strategies in a Referral Oncology Unit. *Cancers*, **2021**, 13, 6.6 1

774 Multiple Myeloma Bone Disease: Implication of MicroRNAs in Its Molecular Background. *International Journal of Molecular Sciences*, **2021**, 22, 6.3 12

773 High Prevalence of Anti-PF4 Antibodies Following ChAdOx1 nCov-19 (AZD1222) Vaccination Even in the Absence of Thrombotic Events. *Vaccines*, **2021**, 9, 5.3 11

772 Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine. *Clinical and Experimental Medicine*, **2021**, 1 4.9 11

771 2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde. *Haematologica*, **2021**, 106, 2799-2812 6.6 4

770 Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma. *Future Oncology*, **2021**, 17, 2499-2512 3.6 0

769 Antibody Response After Initial Vaccination for SARS-CoV-2 in Patients With Amyloidosis. *HemaSphere*, **2021**, 5, e614 0.3 5

768 Kinetics of Anti-SARS-CoV-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers. *Cells*, **2021**, 10, 7.9 12

767 SARS-CoV-2 antibody kinetics eight months from COVID-19 onset: Persistence of spike antibodies but loss of neutralizing antibodies in 24% of convalescent plasma donors. *European Journal of Internal Medicine*, **2021**, 89, 87-96 3.9 21

766 Systemic IL-15, IFN- γ and IP-10/CXCL10 signature associated with effective immune response to SARS-CoV-2 in BNT162b2 mRNA vaccine recipients. *Cell Reports*, **2021**, 36, 109504 10.6 30

765 Bone Marrow Microenvironment Interplay and Current Clinical Practice in Multiple Myeloma: A Review of the Balkan Myeloma Study Group. *Journal of Clinical Medicine*, **2021**, 10, 5.1 3

764 Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients. *BMC Medicine*, **2021**, 19, 208 11.4 19

763 The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment. *Blood Cancer Journal*, **2021**, 11, 138 7 46

762	Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective Study. <i>Cancers</i> , 2021 , 13,	6.6	16
761	Myeloma patients with COVID-19 have superior antibody responses compared to patients fully vaccinated with the BNT162b2 vaccine. <i>British Journal of Haematology</i> , 2021 ,	4.5	6
760	Poor neutralizing antibody responses in 106 patients with WM after vaccination against SARS-CoV-2: a prospective study. <i>Blood Advances</i> , 2021 , 5, 4398-4405	7.8	9
759	FlowCT for the analysis of large immunophenotypic datasets and biomarker discovery in cancer immunology. <i>Blood Advances</i> , 2021 ,	7.8	2
758	Consolidation with a short course of daratumumab in patients with AL amyloidosis or light chain deposition disease. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2021 , 1-8	2.7	1
757	Targeting the Interplay between HDACs and DNA Damage Repair for Myeloma Therapy. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	2
756	Occupational Exposure and Multiple Myeloma Risk: An Updated Review of Meta-Analyses. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	3
755	Kinetics of Nucleocapsid, Spike and Neutralizing Antibodies, and Viral Load in Patients with Severe COVID-19 Treated with Convalescent Plasma. <i>Viruses</i> , 2021 , 13,	6.2	1
754	Control of SARS-CoV-2 infection after Spike DNA or Spike DNA+Protein co-immunization in rhesus macaques. <i>PLoS Pathogens</i> , 2021 , 17, e1009701	7.6	4
753	BCMA in Multiple Myeloma-A Promising Key to Therapy. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	4
752	SARS-CoV-2 neutralizing antibodies after first vaccination dose in breast cancer patients receiving CDK4/6 inhibitors. <i>Breast</i> , 2021 , 60, 58-61	3.6	7
751	Neutralizing Antibody Testing in Patients With Multiple Myeloma Following COVID-19 Vaccination. <i>JAMA Oncology</i> , 2021 ,	13.4	1
750	A Cancer-Related microRNA Signature Shows Biomarker Utility in Multiple Myeloma. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	1
749	Carfilzomib-associated renal toxicity is common and unpredictable: a comprehensive analysis of 114 multiple myeloma patients. <i>Blood Cancer Journal</i> , 2020 , 10, 109	7	7
748	Deep Phenotyping Reveals Distinct Immune Signatures Correlating with Prognostication, Treatment Responses, and MRD Status in Multiple Myeloma. <i>Cancers</i> , 2020 , 12,	6.6	6
747	Long PFS of more than 7 years is achieved in 9% of myeloma patients in the era of conventional chemotherapy and of first-generation novel anti-myeloma agents: a single-center experience over 20-year period. <i>Annals of Hematology</i> , 2020 , 99, 1257-1264	3	5
746	Primary plasma cell leukemia presenting as secondary pulmonary alveolar proteinosis. <i>Leukemia and Lymphoma</i> , 2020 , 61, 2246-2249	1.9	
745	Minimal Residual Disease in Multiple Myeloma: Current Landscape and Future Applications With Immunotherapeutic Approaches. <i>Frontiers in Oncology</i> , 2020 , 10, 860	5.3	16

744	Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRd. <i>Expert Review of Hematology</i> , 2020 , 13, 421-433	2.8	16
743	Efficacy of Panobinostat for the Treatment of Multiple Myeloma. <i>Journal of Oncology</i> , 2020 , 2020, 7131803	0.3	21
742	Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple myeloma. <i>Blood Cancer Journal</i> , 2020 , 10, 25	7	10
741	Upfront Daratumumab With Lenalidomide and Dexamethasone for POEMS Syndrome. <i>HemaSphere</i> , 2020 , 4, e381	0.3	4
740	The Emerging Role of Convalescent Plasma in the Treatment of COVID-19. <i>HemaSphere</i> , 2020 , 4, e409	0.3	30
739	Real-world data on incidence, clinical characteristics and outcome of patients with macrofocal multiple myeloma (MFMM) in the era of novel therapies: A study of the Greco-Israeli collaborative myeloma working group. <i>American Journal of Hematology</i> , 2020 , 95, 465-471	7.1	5
738	Monitoring Plasma Cell Dyscrasias With Cell-free DNA Analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020 , 20, e905-e909	2	3
737	Multiple Myeloma and Thrombosis: Prophylaxis and Risk Prediction Tools. <i>Cancers</i> , 2020 , 12,	6.6	18
736	Antibody therapies for multiple myeloma. <i>Expert Opinion on Biological Therapy</i> , 2020 , 20, 295-303	5.4	5
735	Early Relapse After Autologous Transplant Is Associated With Very Poor Survival and Identifies an Ultra-High-Risk Group of Patients With Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020 , 20, 445-452	2	9
734	Cell-free DNA analysis for the detection of MYD88 and CXCR4 mutations in IgM monoclonal gammopathies; an update with clinicopathological correlations. <i>American Journal of Hematology</i> , 2020 , 95, E148-E150	7.1	7
733	Hematological findings and complications of COVID-19. <i>American Journal of Hematology</i> , 2020 , 95, 834-847	8.47	861
732	Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma. <i>Annals of Hematology</i> , 2020 , 99, 1049-1061	3	12
731	Clinical Updates Regarding Multiple Myeloma From the 2019 American Society of Hematology Annual Meeting. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020 , 20, 499-508	2	9
730	IMiD Retreatment in Patients Refractory to Both an IMiD and an Anti-CD38 Antibody Induces Significant Response Rates Post Anti-CD38 Exposure. <i>Blood</i> , 2020 , 136, 12-12	2.2	
729	Carfilzomib 56mg/m ² Twice-Weekly in Combination with Dexamethasone and Daratumumab (KdD) Versus Daratumumab in Combination with 8 Cycles of Bortezomib and Dexamethasone (DvD); A Matching-Adjusted Indirect Treatment Comparison. <i>Blood</i> , 2020 , 136, 8-9	2.2	1
728	A Prospective Study and Identification of Genomewide Association Markers of Familial Predisposition to Plasma Cell Dyscrasias. <i>Blood</i> , 2020 , 136, 8-8	2.2	
727	Carfilzomib-Induced Hypertension Is Mediated By Ion Channel Dysregulation in the Kidneys; The Potent Role of AMP-Activated Kinase β . <i>Blood</i> , 2020 , 136, 34-35	2.2	0

726	Daratumumab with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment: Results on Efficacy and Safety of the Phase 2 Dare Study. <i>Blood</i> , 2020 , 136, 48-49	2.2	6
725	Short Daratumumab Consolidation in Patients with AL Amyloidosis or Lcdd Improves Complete Response Rates and Modifies Bone Marrow Microenvironment. <i>Blood</i> , 2020 , 136, 25-25	2.2	0
724	Efficacy and Tolerability of Daratumumab with Ixazomib and Dexamethasone in Patients with One Prior Lenalidomide-Based Regimen: Preliminary Results of the Phase 2 Daria Study. <i>Blood</i> , 2020 , 136, 19-20	2.2	
723	Efficacy of Daratumumab Monotherapy on Bone Metabolism of Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results from the Phase 2 Rebuild Study. <i>Blood</i> , 2020 , 136, 29-29 ^{2,2}		
722	Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) As a Biomarker of Renal Outcomes in AL Amyloidosis. <i>Blood</i> , 2020 , 136, 33-33	2.2	
721	The Addition of IMiDs for Patients with Daratumumab-Refractory Multiple Myeloma Can Overcome Refractoriness to Both Agents. <i>Blood</i> , 2020 , 136, 21-21	2.2	0
720	The Role of Low Dose Whole Body CT in the Detection of Progression of Patients with Smoldering Multiple Myeloma. <i>Blood</i> , 2020 , 136, 6-7	2.2	
719	Pomalidomide Plus Low Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Results of the Real-World 'Powerful' Study. <i>Blood</i> , 2020 , 136, 33-35	2.2	
718	Real-World Evidence of the Use of Carfilzomib Among Multiple Myeloma Patients with at Least One Prior Therapy across 10 European Countries and Israel. <i>Blood</i> , 2020 , 136, 38-39	2.2	0
717	Real-World Evidence of the Use of Approved Carfilzomib Regimens in Patients Previously Exposed or Refractory to Lenalidomide: Updated Results from a Prospective Observational Study. <i>Blood</i> , 2020 , 136, 9-10	2.2	
716	Carfilzomib-Induced Cardiotoxicity in an In Vivo Model of Aging. <i>Blood</i> , 2020 , 136, 18-18	2.2	
715	T Cell Immunoprofiling of Patients with Relapsed and/or Refractory Myeloma Who Receive Daratumumab Monotherapy: Longitudinal Analysis during 7 Cycle Follow-up of the Rebuild Phase 2 Study. <i>Blood</i> , 2020 , 136, 28-28	2.2	1
714	Longitudinal Immunogenomic Profiling of Tumor and Immune Cells for Minimally-Invasive Monitoring of Smoldering Multiple Myeloma (SMM): The Immunocell Study. <i>Blood</i> , 2020 , 136, 1-2	2.2	1
713	Effectiveness and Safety of Ixazomib-Based Therapy in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated Outside the Clinical Trial Setting Via an Early Access Program (EAP) in Europe: Second Interim Analysis of the 'Use Via Early Access to Ixazomib' (UVEA-IXA) Study. <i>Blood</i> , 2020 , 136, 13-14	2.2	1
712	DREAMM-9: Phase III study of belantamab mafodotin plus VRd versus VRd alone in transplant-ineligible newly diagnosed multiple myeloma (TI NDMM).. <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS8556-TPS8556	2.2	6
711	Circulating tumor DNA-based predictive biomarkers in breast cancer clinical trials: a narrative review. <i>Annals of Translational Medicine</i> , 2020 , 8, 1603	3-2	4
710	Plasma Cell Leukemia - Facts and Controversies: More Questions than Answers?. <i>Clinical Hematology International</i> , 2020 , 2, 133-142	1.8	1
709	Peripheral Blood Immune Profiling of Convalescent Plasma Donors Reveals Alterations in Specific Immune Subpopulations Even at 2 Months Post SARS-CoV-2 Infection. <i>Viruses</i> , 2020 , 13,	6.2	18

708	CCL3 Signaling in the Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2020 , 1231, 13-21	3.6	22
707	Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN). <i>Leukemia</i> , 2020 , 34, 2000-2011	10.7	71
706	Significant reduction in the visits to the emergency room department during the COVID-19 pandemic in a tertiary hospital in Greece: Indirect victims of the pandemic?. <i>Medicine (United States)</i> , 2020 , 99, e23845	1.8	9
705	Multiple myeloma: Role of autologous transplantation. <i>Cancer Treatment Reviews</i> , 2020 , 82, 101929	14.4	21
704	Emerging Insights Into the Role of the Hippo Pathway in Multiple Myeloma and Associated Bone Disease. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020 , 20, 57-62	2	8
703	Seroprevalence of Antibodies against SARS-CoV-2 among the Personnel and Students of the National and Kapodistrian University of Athens, Greece: A Preliminary Report. <i>Life</i> , 2020 , 10,	3	20
702	The Role of Low Dose Whole Body CT in the Detection of Progression of Patients with Smoldering Multiple Myeloma. <i>Blood Cancer Journal</i> , 2020 , 10, 93	7	7
701	Characterization of a PERK Kinase Inhibitor with Anti-Myeloma Activity. <i>Cancers</i> , 2020 , 12,	6.6	3
700	Clinical Utility of Selinexor/Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma: A Review of Current Evidence and Patient Selection. <i>OncoTargets and Therapy</i> , 2020 , 13, 6405-6416	4.4	5
699	Chemotherapy resumption in ovarian cancer patient diagnosed with COVID-19. <i>Gynecologic Oncology Reports</i> , 2020 , 33, 100615	1.3	5
698	Ex Vivo Models Simulating the Bone Marrow Environment and Predicting Response to Therapy in Multiple Myeloma. <i>Cancers</i> , 2020 , 12,	6.6	9
697	Organ-specific manifestations of COVID-19 infection. <i>Clinical and Experimental Medicine</i> , 2020 , 20, 493-506	1.6	194
696	Investigating the Vascular Toxicity Outcomes of the Irreversible Proteasome Inhibitor Carfilzomib. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	4
695	Renal pathology in patients with monoclonal gammopathy or multiple myeloma: monoclonal immunoglobulins are not always the cause. <i>Leukemia and Lymphoma</i> , 2020 , 61, 3247-3250	1.9	0
694	Response of an oncology unit in the midst of the COVID-19 outbreak. <i>Journal of Oncology Pharmacy Practice</i> , 2020 , 26, 1947-1952	1.7	1
693	Bone health in cancer: ESMO Clinical Practice Guidelines. <i>Annals of Oncology</i> , 2020 , 31, 1650-1663	10.3	82
692	Derivation and Validation of a Predictive Score for Disease Worsening in Patients with COVID-19. <i>Thrombosis and Haemostasis</i> , 2020 , 120, 1680-1690	7	21
691	Anti-SARS-CoV-2 Antibody Responses in Convalescent Plasma Donors Are Increased in Hospitalized Patients; Subanalyses of a Phase 2 Clinical Study. <i>Microorganisms</i> , 2020 , 8,	4.9	30

690	Clinical characteristics and outcomes of oligosecretory and non-secretory multiple myeloma. <i>Annals of Hematology</i> , 2020 , 99, 1251-1255	3	6
689	Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents. <i>Blood Cancer Journal</i> , 2020 , 10, 40	7	7
688	Non-lethal proteasome inhibition activates pro-tumorigenic pathways in multiple myeloma cells. <i>Journal of Cellular and Molecular Medicine</i> , 2019 , 23, 8010-8018	5.6	2
687	Real World Treatment of Patients with Relapsed/Refractory Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019 , 19, S24-S27	2	1
686	Bortezomib retreatment for relapsed and refractory multiple myeloma in real-world clinical practice. <i>Health Science Reports</i> , 2019 , 2, e104	2.2	6
685	Development of an Initial Conceptual Model of Multiple Myeloma to Support Clinical and Health Economics Decision Making. <i>MDM Policy and Practice</i> , 2019 , 4, 2381468318814253	1.5	6
684	Denosumab effects on serum levels of the bone morphogenetic proteins antagonist noggin in patients with transfusion-dependent thalassemia and osteoporosis. <i>Hematology</i> , 2019 , 24, 318-324	2.2	4
683	Evaluation of MET T1010I and MET rs40239 single-nucleotide polymorphisms in triple-negative breast cancer: a case-control study. <i>OncoTargets and Therapy</i> , 2019 , 12, 4195-4202	4.4	
682	International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. <i>Lancet Oncology, The</i> , 2019 , 20, e302-e312	21.7	166
681	A revised international prognostic score system for Waldenström's macroglobulinemia. <i>Leukemia</i> , 2019 , 33, 2654-2661	10.7	27
680	The Growth Differentiation Factor-15 (GDF-15) levels are increased in patients with compound heterozygous sickle cell and beta-thalassemia (HbS/β) correlate with markers of hemolysis, iron burden, coagulation, endothelial dysfunction and pulmonary hypertension. <i>Blood Cells, Molecules, and Diseases</i> , 2019 , 77, 137-141	2.1	6
679	Response to Comment-Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published in <i>Lancet Oncology</i> . <i>Dentistry Journal</i> , 2019 , 7,	3.1	3
678	Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody. <i>Cancer Treatment Reviews</i> , 2019 , 76, 57-67	14.4	50
677	Multiple Myeloma Bone Disease 2019 , 329-340		
676	Activin-A is elevated in patients with thalassemia major and double heterozygous sickle cell/beta-thalassemia and correlates with markers of hemolysis and bone mineral density. <i>Annals of Hematology</i> , 2019 , 98, 1583-1592	3	1
675	Evaluation of regulatory T cells (Tregs) alterations in patients with multiple myeloma treated with bortezomib or lenalidomide plus dexamethasone: correlations with treatment outcome. <i>Annals of Hematology</i> , 2019 , 98, 1457-1466	3	9
674	INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma. <i>Future Oncology</i> , 2019 , 15, 1411-1428	3.6	10
673	Pulmonary function abnormalities are common in patients with multiple myeloma and are independently associated with worse outcome. <i>Annals of Hematology</i> , 2019 , 98, 1427-1434	3	3

672	Updates on thrombotic events associated with multiple myeloma. <i>Expert Review of Hematology</i> , 2019 , 12, 355-365	2.8	6
671	A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in four European countries: Austria, Belgium, Greece, and Italy. <i>Journal of Medical Economics</i> , 2019 , 22, 766-776	2.4	3
670	Multiple Myeloma: Clinical Updates From the American Society of Hematology Annual Meeting 2018. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019 , 19, e324-e336	2	10
669	Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension. <i>Journal of Internal Medicine</i> , 2019 , 286, 63-74	10.8	26
668	Role of the RANK/RANKL Pathway in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2019 , 25, 12-20	12.9	24
667	GFR estimation in lenalidomide treatment of multiple myeloma patients: a prospective cohort study. <i>Clinical and Experimental Nephrology</i> , 2019 , 23, 199-206	2.5	
666	Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2019 , 60, 163-171	1.9	8
665	Reactive Vasodilation Predicts Mortality in Primary Systemic Light-Chain Amyloidosis. <i>Circulation Research</i> , 2019 , 125, 744-758	15.7	18
664	Monoclonal antibodies against RANKL and sclerostin for myeloma-related bone disease: can they change the standard of care?. <i>Expert Review of Hematology</i> , 2019 , 12, 651-663	2.8	10
663	Elotuzumab in combination with pomalidomide and dexamethasone for the treatment of multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2019 , 19, 921-928	3.5	3
662	Natural History of Skeletal Related Events in Patients with Multiple Myeloma Who Received First- and Second- Line Therapy with Novel Agents: Results from a Single Center Analysis in 620 Patients. <i>Blood</i> , 2019 , 134, 4326-4326	2.2	1
661	Consolidation with Carfilzomib, Lenalidomide and Dexamethasone (KRd) Following ASCT Results in High Rates of Minimal Residual Disease Negativity and Improves Bone Metabolism, in the Absence of Bisphosphonates, Among Newly Diagnosed Patients with Multiple Myeloma. <i>Blood</i> , 2019 , 134, 3118-3118	2.2	4
660	Impact of Daratumumab Monotherapy on Bone Parameters in Patients with Relapsed and/or Refractory Multiple Myeloma Who Have Received at Least 2 Prior Lines of Therapy Including Lenalidomide and a Proteasome Inhibitor; Interim Analysis of a Phase 2 Study (the REBUILD Study). <i>Blood</i> , 2019 , 134, 1837-1837	2.2	2
659	Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Is a Renal Biomarker with Potential Clinical Applications in Monoclonal Gammopathy of Renal Significance (MGRS). <i>Blood</i> , 2019 , 134, 3126-3126	2.2	0
658	Real-World (RW) Multiple Myeloma (MM) Patients (Pts) Remain Under-Represented in Clinical Trials Based on Standard Laboratory Parameters and Baseline Characteristics: Analysis of over 3,000 Pts from the Insight MM Global, Prospective, Observational Study. <i>Blood</i> , 2019 , 134, 1887-1887	2.2	5
657	Closing the Efficacy and Effectiveness Gap: Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) in Routine Clinical Practice Remain Comparable to the Outcomes Reported in the Phase 3 Tourmaline-MM1 Study. <i>Blood</i> , 2019 , 134, 1815-1815	2.2	2
656	Progression-Free Survival Analysis of Denosumab Vs Zoledronic Acid in Intent to Transplant Multiple Myeloma Patients Based on Treatment Regimen and Baseline Characteristics. <i>Blood</i> , 2019 , 134, 606-606	2.2	9
655	Next Generation Flow Cytometry Provides a Standardized, Highly Sensitive and Informative Method for the Analysis of Circulating Plasma Cells in Newly Diagnosed Multiple Myeloma: A Single Center Study in 182 Patients. <i>Blood</i> , 2019 , 134, 4338-4338	2.2	1

654	A Molecular Signature of Three tRNA-Derived RNA Fragments May Discriminate Smoldering from Symptomatic Multiple Myeloma Patients. <i>Blood</i> , 2019 , 134, 5528-5528	2.2	1
653	Real-world use of carfilzomib among multiple myeloma patients with at least one prior therapy.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e19515-e19515	2.2	1
652	Circulating noggin levels following treatment with denosumab or teriparatide in postmenopausal women with low bone mass. <i>Journal of Musculoskeletal Neuronal Interactions</i> , 2019 , 19, 253-257	1.3	
651	PS1394 FLOW-MEDIATED DILATATION AND AORTIC BLOOD PRESSURE PREDICT CARDIOVASCULAR ADVERSE EVENTS DURING CARFILZOMIB TREATMENT: A PROSPECTIVE STUDY IN PATIENTS WITH RELAPSED/ REFRACTORY MULTIPLE MYELOMA. <i>HemaSphere</i> , 2019 , 3, 639-640	0.3	
650	Efficacy of Daratumumab with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment: An Interim Analysis of a Phase 2 Study (the DARE Study). <i>Blood</i> , 2019 , 134, 1881-1881	2.2	
649	Serum Neutrophil Gelatinase-Associated Lipocalin Independently Predicts for Renal Response in Myeloma Patients with Severe Renal Impairment. <i>Blood</i> , 2019 , 134, 1877-1877	2.2	
648	Accumulation of Endogenous DNA Damage Sustain Malignant Progression and Increase Therapy Resistance in Multiple Myeloma. <i>Blood</i> , 2019 , 134, 1788-1788	2.2	
647	Panobinostat Potentiates Melphalan-Induced Apoptosis of Myeloma Cells and Minimizes Untoward Side Effects in Multiple Myeloma. <i>Blood</i> , 2019 , 134, 2528-2528	2.2	
646	Real-World Evidence of the Use of Carfilzomib and Dexamethasone (Kd) By Lenalidomide-Refractory Status: An Interim Analysis from a Prospective Observational Study. <i>Blood</i> , 2019 , 134, 5578-5578	2.2	
645	Pulmonary Function Tests Reveal Unrecognized Lung Dysfunction and Have Independent Prognostic Significance in Patients with Systemic AL Amyloidosis. <i>Blood</i> , 2019 , 134, 1842-1842	2.2	
644	Synergistic Effect of Carfilzomib and Metformin in Vascular Plasticity; The Emerging Role of Autophagy. <i>Blood</i> , 2019 , 134, 3797-3797	2.2	
643	Non Invasive Evaluation of Bone Marrow Activity in Patients with Sickle Cell Disease: Correlation with Disease Features, Genotype, Markers of Erythropoiesis, Iron Metabolism and Hydroxyurea Treatment. <i>Blood</i> , 2019 , 134, 4821-4821	2.2	
642	Primary Bone Non-Hodgkin's Lymphoma: A Specific Clinical Entity with Aggressive Clinical Course and High Cure Rate - Retrospective Analysis of 102 Patients from Greece. <i>Blood</i> , 2019 , 134, 5340-5340	2.2	
641	Longitudinal T Cell Immunoprofiling of Patients with Relapsed and/or Refractory Myeloma Who Receive Daratumumab Monotherapy: A Subanalysis of a Phase 2 Study (the REBUILD Study). <i>Blood</i> , 2019 , 134, 3167-3167	2.2	2
640	Bone Loss and High Bone Turnover in Patients with Non-Hodgkin's Lymphoma Who Receive Frontline Chemotherapy: Final Results of a Multicenter Prospective Study. <i>Blood</i> , 2019 , 134, 4124-4124	2.2	
639	The Clinical Significance of a Novel microRNA Signature in Multiple Myeloma. <i>Blood</i> , 2019 , 134, 5529-5529		
638	Clinical Impact of an Early Response and of Early Initiation of Salvage Therapy in Patients with Systemic Light Chain (AL) Amyloidosis. <i>Blood</i> , 2019 , 134, 1894-1894	2.2	0
637	Anti-BCMA antibodies in the future management of multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2019 , 19, 319-326	3.5	14

636	The role of cement augmentation with percutaneous vertebroplasty and balloon kyphoplasty for the treatment of vertebral compression fractures in multiple myeloma: a consensus statement from the International Myeloma Working Group (IMWG). <i>Blood Cancer Journal</i> , 2019 , 9, 27	7	36
635	Bone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group. <i>American Journal of Hematology</i> , 2019 , 94, E146-E149	7.1	7
634	Myeloma bone disease: from biology findings to treatment approaches. <i>Blood</i> , 2019 , 133, 1534-1539	2.2	58
633	PS1419 COMPARATIVE EFFECTIVENESS OF TRIPLETS CONTAINING BORTEZOMIB (B), CARFILZOMIB (C), DARATUMUMAB (D), OR IXAZOMIB (I) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) IN ROUTINE CARE IN THE US. <i>HemaSphere</i> , 2019 , 3, 652-653	0.3	1
632	Optimizing Immunomodulatory Drug With Proteasome Inhibitor Combinations in Newly Diagnosed Multiple Myeloma. <i>Cancer Journal (Sudbury, Mass)</i> , 2019 , 25, 2-10	2.2	6
631	Impact of Minimal Residual Disease Detection by Next-Generation Flow Cytometry in Multiple Myeloma Patients with Sustained Complete Remission after Frontline Therapy. <i>HemaSphere</i> , 2019 , 3, e300	0.3	11
630	Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasone. <i>Blood Advances</i> , 2019 , 3, 4095-4103	7.8	9
629	Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone. <i>Blood Advances</i> , 2019 , 3, 3002-3009	7.8	22
628	Treatment of Bing-Neel syndrome with first line sequential chemoimmunotherapy: A case report. <i>Medicine (United States)</i> , 2019 , 98, e17794	1.8	3
627	Elevated vWF Antigen Serum Levels Are Associated With Poor Prognosis, and Decreased Circulating ADAMTS-13 Antigen Levels Are Associated With Increased IgM Levels and Features of WM but not Increased vWF Levels in Patients With Symptomatic WM. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019 , 19, e22-28	2	0
626	Consolidation therapy with the combination of bortezomib and lenalidomide (VR) without dexamethasone in multiple myeloma patients after transplant: Effects on survival and bone outcomes in the absence of bisphosphonates. <i>American Journal of Hematology</i> , 2019 , 94, 400-407	7.1	15
625	Molecular mechanisms of carfilzomib-induced cardiotoxicity in mice and the emerging cardioprotective role of metformin. <i>Blood</i> , 2019 , 133, 710-723	2.2	47
624	Effect of induction therapy with lenalidomide, doxorubicin and dexamethasone on bone remodeling and angiogenesis in newly diagnosed multiple myeloma. <i>International Journal of Cancer</i> , 2019 , 145, 559-568	7.5	7
623	Vulnerability variables among octogenerian myeloma patients: a single-center analysis of 110 patients. <i>Leukemia and Lymphoma</i> , 2019 , 60, 619-628	1.9	5
622	Multiple Myeloma: Clinical Updates From the American Society of Hematology Annual Meeting, 2017. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018 , 18, 321-334	2	13
621	Biology and treatment of myeloma related bone disease. <i>Metabolism: Clinical and Experimental</i> , 2018 , 80, 80-90	12.7	37
620	Other Complications of Multiple Myeloma. <i>Hematologic Malignancies</i> , 2018 , 141-156	0	1
619	Bone Disease. <i>Hematologic Malignancies</i> , 2018 , 111-140	0	

618	Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis. <i>Blood</i> , 2018 , 131, 1568-1575	2.2	35
617	The multiple myeloma treatment landscape: international guideline recommendations and clinical practice in Europe. <i>Expert Review of Hematology</i> , 2018 , 11, 219-237	2.8	21
616	Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. <i>Lancet Oncology</i> , 2018 , 19, 370-381	21.7	216
615	Healthcare-resource utilization associated with radiation to bone across eight European countries: Results from a retrospective study. <i>Journal of Bone Oncology</i> , 2018 , 10, 49-56	4.5	1
614	Pathogenesis of bone disease in multiple myeloma: from bench to bedside. <i>Blood Cancer Journal</i> , 2018 , 8, 7	7	144
613	Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. <i>Leukemia</i> , 2018 , 32, 1542-1560	10.7	40
612	Circulating Soluble Receptor Activator of Nuclear Factor Kappa B Ligand and C-C Motif Ligand 3 Correlate With Survival in Patients With Waldenström Macroglobulinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018 , 18, 431-437	2	3
611	Going the distance: Are we losing patients along the multiple myeloma treatment pathway?. <i>Critical Reviews in Oncology/Hematology</i> , 2018 , 126, 19-23	7	6
610	Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group. <i>Blood Cancer Journal</i> , 2018 , 8, 31	7	24
609	A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in the United States of America. <i>Journal of Medical Economics</i> , 2018 , 21, 525-536	2.4	14
608	Bone metabolism markers and angiogenic cytokines as regulators of human hematopoietic stem cell mobilization. <i>Journal of Bone and Mineral Metabolism</i> , 2018 , 36, 399-409	2.9	3
607	Cardiovascular adverse events in modern myeloma therapy - Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA). <i>Haematologica</i> , 2018 , 103, 1422-1432	6.6	44
606	European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. <i>Leukemia</i> , 2018 , 32, 1883-1898	10.7	58
605	Bortezomib-based therapy for relapsed/refractory multiple myeloma in real-world medical practice. <i>European Journal of Haematology</i> , 2018 , 101, 556-565	3.8	8
604	Mild leukopenia following denosumab treatment in a woman with postmenopausal osteoporosis. <i>Endocrine</i> , 2018 , 62, 487-489	4	0
603	Detection of MYD88 and CXCR4 mutations in cell-free DNA of patients with IgM monoclonal gammopathies. <i>Leukemia</i> , 2018 , 32, 2617-2625	10.7	25
602	Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel. <i>Journal of Hematology and Oncology</i> , 2018 , 11, 10	22.4	89
601	Semaphorin 4D correlates with increased bone resorption, hypercalcemia, and disease stage in newly diagnosed patients with multiple myeloma. <i>Blood Cancer Journal</i> , 2018 , 8, 42	7	22

600	Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysis. <i>JAMA Oncology</i> , 2018 , 4, 1389-1397	13.4	48
599	Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN). <i>Leukemia</i> , 2018 , 32, 1697-1712	10.7	61
598	Carfilzomib-Associated Renal Toxicity Is Common and Unpredictable: An Analysis of 114 Patients. <i>Blood</i> , 2018 , 132, 1966-1966	2.2	2
597	Ixazomib Plus Lenalidomide-Dexamethasone (IRd) in Relapsed/Refractory Multiple Myeloma (MM) Patients (Pts) - Effectiveness in Routine Clinical Practice Is Similar to the Efficacy in the Phase 3 Tourmaline-MM1 Trial: A Pooled Analysis from the Insight MM Observational Study and the Czech Study of Multiple Myeloma (CMMO). <i>Blood</i> , 2018 , 132, 1874-1874	2.2	5
596	Progression-Free Survival Subset Analysis - Denosumab Vs Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Double-Dummy, Randomized Controlled Phase 3 Study. <i>Blood</i> , 2018 , 132, 1969-1969	2.2	8
595	Real-World Data on Incidence, Clinical Characteristics and Outcome of Patients with Macrofocal Multiple Myeloma (MFMM) in the Era of Novel Therapies: A Study of the Greco-Israeli Collaborative Myeloma Working Group. <i>Blood</i> , 2018 , 132, 3295-3295	2.2	1
594	Pomalidomide and dexamethasone (pom-dex) with or without daratumumab (DARA) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): A multicenter, randomized, phase 3 study (APOLLO).. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS8059-TPS8059	2.2	8
593	How I treat elderly patients with plasma cell dyscrasias. <i>Aging</i> , 2018 , 10, 4248-4268	5.6	5
592	Molecular responses to therapeutic proteasome inhibitors in multiple myeloma patients are donor-, cell type- and drug-dependent. <i>Oncotarget</i> , 2018 , 9, 17797-17809	3.3	7
591	Evaluation of pre-mir-34a rs72631823 single nucleotide polymorphism in triple negative breast cancer: A case-control study. <i>Oncotarget</i> , 2018 , 9, 36906-36913	3.3	5
590	Practical Considerations for Bone Health in Multiple Myeloma 2018 , 131-167		
589	Second Primary Malignancies and Disease Transformation in Newly Diagnosed Symptomatic Patients with Waldenstrom's Macroglobulinemia: An Analysis from the Greek Myeloma Study Group. <i>Blood</i> , 2018 , 132, 1978-1978	2.2	
588	Carfilzomib Induces Acute Endothelial Dysfunction Which Correlates with the Occurrence of Cardiovascular Events. <i>Blood</i> , 2018 , 132, 3247-3247	2.2	
587	In Newly Diagnosed Multiple Myeloma Patients, Longer Procoagulant Phospholipid-Dependent Clotting Time, Higher Levels of P-Selectin, D-Dimers and Thrombin Generation Peak Are Associated with Increased Risk of Resistance to Treatment: Results of the Prospective Roadmap-MM Study. <i>Blood</i> , 2018 , 132, 2014-2014	2.2	
586	Metformin Restores AMPK Alpha-Mediated Autophagy and Prevents Carfilzomib-Induced Cardiotoxicity In Vivo. <i>Blood</i> , 2018 , 132, 3214-3214	2.2	
585	Consolidation with a Short Course of Daratumumab Improves Complete Response Rates in Patients with AL Amyloidosis or Lcdd. <i>Blood</i> , 2018 , 132, 3246-3246	2.2	
584	Functional Cure, Defined As PFS of More Than 7 Years, Is Achieved in 9% of Myeloma Patients in the Era of Conventional Chemotherapy and of First-Generation Novel Anti-Myeloma Agents; A Single-Center Experience over 20-Year Period. <i>Blood</i> , 2018 , 132, 1968-1968	2.2	
583	Transplant Status Does Not Impact the Selection of Induction Regimens for Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) in the Insight MM Prospective, Observational Study. <i>Blood</i> , 2018 , 132, 3289-3289	2.2	1

582	Systemic Mastocytosis: Management and Outcome. Data Analysis from the Greek Registry. <i>Blood</i> , 2018 , 132, 5463-5463	2.2	
581	From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives. <i>Haematologica</i> , 2018 , 103, 197-211	6.6	78
580	The role of sclerostin/dickkopf-1 and receptor activator of nuclear factor kB ligand/osteoprotegerin signalling pathways in the development of osteoporosis in patients with haemophilia A and B: A cross-sectional study. <i>Haemophilia</i> , 2018 , 24, 316-322	3.3	12
579	Rare manifestations of extramedullary myeloma: testicular plasmacytomas. <i>Leukemia and Lymphoma</i> , 2018 , 59, 2002-2004	1.9	3
578	The role of ibrutinib in Waldenström macroglobulinemia. <i>Expert Opinion on Orphan Drugs</i> , 2018 , 6, 85-89	1.1	
577	Study of bone metabolism and angiogenesis in patients undergoing high-dose chemotherapy/autologous hematopoietic stem cell transplantation. <i>European Journal of Haematology</i> , 2018 , 100, 131-139	3.8	1
576	The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents. <i>Blood</i> , 2018 , 131, 464-467	2.2	36
575	Coexistence of leishmaniasis and multiple myeloma in the era of monoclonal antibody (anti-CD38 or anti-SLAMF7) containing triplets: one shared story of two exceptional cases. <i>Leukemia and Lymphoma</i> , 2018 , 59, 983-987	1.9	3
574	Retreatment and prolonged therapy with subcutaneous bortezomib in patients with relapsed multiple myeloma: A randomized, controlled, phase III study. <i>European Journal of Haematology</i> , 2018 , 100, 10-19	3.8	6
573	Efficacy of lenalidomide as salvage therapy for patients with AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2018 , 25, 234-241	2.7	15
572	Noggin levels in nonalcoholic fatty liver disease: the effect of vitamin E treatment. <i>Hormones</i> , 2018 , 17, 573-579	3.1	3
571	Longer procoagulant phospholipid-dependent clotting time, lower endogenous thrombin potential and higher tissue factor pathway inhibitor concentrations are associated with increased VTE occurrence in patients with newly diagnosed multiple myeloma: results of the prospective	7	17
570	Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group. <i>Blood Cancer Journal</i> , 2018 , 8, 95	7	34
569	Multiple Myeloma: Criteria for Diagnosis and Response to Therapy 2018 , 651-658		
568	Multiple Myeloma: How to Use Modern Imaging in Every Day Clinical Practice? 2018 , 671-676		
567	Management of multiple myeloma bone disease: impact of treatment on renal function. <i>Expert Review of Hematology</i> , 2018 , 11, 881-888	2.8	5
566	Emerging Data on Management and Imaging of Myeloma Bone Disease. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018 , 18, S80-S82	2	
565	European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when. <i>Haematologica</i> , 2018 , 103, 1772-1784	6.6	46

564	Variation of endothelium-related hemostatic factors during sepsis. <i>Microcirculation</i> , 2018 , 25, e12500	2.9	7
563	Denosumab in transfusion-dependent thalassemia osteoporosis: a randomized, placebo-controlled, double-blind phase 2b clinical trial. <i>Blood Advances</i> , 2018 , 2, 2837-2847	7.8	9
562	The role of biphosphonates in the management of thalassemia-induced osteoporosis: a systematic review and meta-analysis. <i>Hormones</i> , 2018 , 17, 153-166	3.1	6
561	Optimizing therapy in bortezomib-exposed patients with multiple myeloma. <i>Expert Review of Hematology</i> , 2018 , 11, 463-469	2.8	1
560	Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis. <i>Blood Cancer Journal</i> , 2018 , 8, 46	7	35
559	Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival. <i>Annals of Hematology</i> , 2018 , 97, 1671-1682	3	7
558	Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018 , 18, e401-e419	2	37
557	Emerging treatment approaches for myeloma-related bone disease. <i>Expert Review of Hematology</i> , 2017 , 10, 217-228	2.8	11
556	Efficacy and safety of elotuzumab for the treatment of multiple myeloma. <i>Expert Opinion on Drug Safety</i> , 2017 , 16, 237-245	4.1	4
555	Low periostin levels in adult patients with Langerhans cell histiocytosis are independently associated with the disease activity. <i>Metabolism: Clinical and Experimental</i> , 2017 , 71, 198-201	12.7	1
554	Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2017 , 28, iv52-iv61	10.3	426
553	When to recommend a second autograft in patients with relapsed myeloma?. <i>Leukemia and Lymphoma</i> , 2017 , 58, 781-787	1.9	3
552	Outcomes of newly diagnosed myeloma patients requiring dialysis: renal recovery, importance of rapid response and survival benefit. <i>Blood Cancer Journal</i> , 2017 , 7, e571	7	20
551	Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. <i>Leukemia</i> , 2017 , 31, 2443-2448	10.7	169
550	Addition of cyclophosphamide and higher doses of dexamethasone do not improve outcomes of patients with AL amyloidosis treated with bortezomib. <i>Blood Cancer Journal</i> , 2017 , 7, e570	7	24
549	Genetic factors related with early onset of osteonecrosis of the jaw in patients with multiple myeloma under zoledronic acid therapy. <i>Leukemia and Lymphoma</i> , 2017 , 58, 2304-2309	1.9	11
548	Renal outcomes in patients with AL amyloidosis: Prognostic factors, renal response and the impact of therapy. <i>American Journal of Hematology</i> , 2017 , 92, 632-639	7.1	37
547	Effects of single-agent bortezomib as post-transplant consolidation therapy on multiple myeloma-related bone disease: a randomized phase II study. <i>British Journal of Haematology</i> , 2017 , 178, 61-71	4.5	12

546	Role of F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. <i>Lancet Oncology, The</i> , 2017 , 18, e206-e217	21.7	275
545	Multiple Myeloma: Clinical Updates From the American Society of Hematology Annual Meeting 2016. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017 , 17, 329-339	2	13
544	Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma. <i>Haematologica</i> , 2017 , 102, 593-599	6.6	56
543	Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma. <i>British Journal of Haematology</i> , 2017 , 176, 783-795	4.5	30
542	Current treatment options and investigational drugs for Waldenstrom's Macroglobulinemia. <i>Expert Opinion on Investigational Drugs</i> , 2017 , 26, 197-205	5.9	10
541	Hematologic and renal improvement of monoclonal immunoglobulin deposition disease after treatment with bortezomib-based regimens. <i>Leukemia and Lymphoma</i> , 2017 , 58, 1832-1839	1.9	17
540	Mechanisms of bone destruction in multiple myeloma. <i>European Journal of Cancer Care</i> , 2017 , 26, e12761.4	1.4	30
539	Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group. <i>Blood Cancer Journal</i> , 2017 , 7, e599	7	83
538	Clonal evolution is a prognostic factor for the clinical progression of monoclonal B-cell lymphocytosis. <i>Blood Cancer Journal</i> , 2017 , 7, e597	7	2
537	Management of Early Relapse, How to Navigate the Choices. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017 , 17, S137-S139	2	
536	Low circulating mannan-binding lectin levels correlate with increased frequency and severity of febrile episodes in myeloma patients who undergo ASCT and do not receive antibiotic prophylaxis. <i>Bone Marrow Transplantation</i> , 2017 , 52, 1537-1542	4.4	2
535	Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel antimyeloma therapies. <i>European Journal of Haematology</i> , 2017 , 99, 409-414 ^{3.8}	3.8	24
534	Dynamic contrast-enhanced magnetic resonance imaging parameters correlate with advanced revised-ISS and angiopoietin-1/angiopoietin-2 ratio in patients with multiple myeloma. <i>Annals of Hematology</i> , 2017 , 96, 1707-1714	3	4
533	An overview of the role of carfilzomib in the treatment of multiple myeloma. <i>Expert Opinion on Pharmacotherapy</i> , 2017 , 18, 1883-1897	4	18
532	Phase 2 study of ofatumumab, fludarabine and cyclophosphamide in relapsed/refractory Waldenström's macroglobulinemia. <i>Leukemia and Lymphoma</i> , 2017 , 58, 1506-1508	1.9	8
531	Second primary malignancies in multiple myeloma: an overview and IMWG consensus. <i>Annals of Oncology</i> , 2017 , 28, 228-245	10.3	66
530	Circulating periostin in patients with nonalcoholic fatty liver disease. <i>Endocrine</i> , 2017 , 56, 438-441	4	4
529	Quantitative Diffusion-weighted Imaging of the Bone Marrow: An Adjunct Tool for the Diagnosis of a Diffuse MR Imaging Pattern in Patients with Multiple Myeloma. <i>Radiology</i> , 2017 , 282, 484-493	20.5	61

528	Cadherin-11 (CDH11) expression in the peripheral blood of patients with active Multiple Myeloma. <i>British Journal of Haematology</i> , 2017 , 177, 813-816	4.5	1
527	Serum free immunoglobulin light chain fingerprint identifies a subset of newly diagnosed multiple myeloma patients with worse outcome. <i>Hematological Oncology</i> , 2017 , 35, 734-740	1.3	5
526	Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network. <i>Leukemia</i> , 2017 ,	10.7	7
525	Milder degenerative effects of Carfilzomib vs. Bortezomib in the Drosophila model: a link to clinical adverse events. <i>Scientific Reports</i> , 2017 , 7, 17802	4.9	13
524	Cardiac and renal complications of carfilzomib in patients with multiple myeloma. <i>Blood Advances</i> , 2017 , 1, 449-454	7.8	67
523	Periostin and sclerostin levels in juvenile Paget's disease. <i>Clinical Cases in Mineral and Bone Metabolism</i> , 2017 , 14, 269-271		1
522	Circulating sclerostin and Dickkopf-1 levels in patients with nonalcoholic fatty liver disease. <i>Journal of Bone and Mineral Metabolism</i> , 2016 , 34, 447-56	2.9	13
521	PET/CT in primary mediastinal large B-cell lymphoma responding to rituximab-CHOP: An analysis of 106 patients regarding prognostic significance and implications for subsequent radiotherapy. <i>Leukemia</i> , 2016 , 30, 238-42	10.7	33
520	Recent Data Supporting Novel Management Strategies for Patients With Multiple Myeloma. <i>JAMA Oncology</i> , 2016 , 2, 1261-1262	13.4	
519	Current treatments for renal failure due to multiple myeloma. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 2165-2177	4	17
518	International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. <i>Lancet Oncology</i> , 2016 , 17, e328-e346	21.7	1155
517	Bone health in the elderly cancer patient: A SIOG position paper. <i>Cancer Treatment Reviews</i> , 2016 , 51, 46-53	14.4	30
516	Overexpression of RANKL by invariant NKT cells enriched in the bone marrow of patients with multiple myeloma. <i>Blood Cancer Journal</i> , 2016 , 6, e500	7	8
515	Carfilzomib for treating myeloma. <i>Expert Opinion on Orphan Drugs</i> , 2016 , 4, 989-999	1.1	2
514	Increased circulating VCAM-1 correlates with advanced disease and poor survival in patients with multiple myeloma: reduction by post-bortezomib and lenalidomide treatment. <i>Blood Cancer Journal</i> , 2016 , 6, e428	7	11
513	An international, multicenter, prospective, observational study of neutropenia in patients being treated with lenalidomide + dexamethasone for relapsed or relapsed/refractory multiple myeloma (RR-MM). <i>American Journal of Hematology</i> , 2016 , 91, 806-11	7.1	7
512	Cost of skeletal complications from bone metastases in six European countries. <i>Journal of Medical Economics</i> , 2016 , 19, 611-8	2.4	19
511	Is it possible to cure myeloma without allogeneic transplantation?. <i>Transfusion and Apheresis Science</i> , 2016 , 54, 63-70	2.4	8

510	International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1544-57	2.2	204
509	Lenalidomide with low- or intermediate-dose dexamethasone in patients with relapsed or refractory myeloma. <i>Leukemia and Lymphoma</i> , 2016 , 57, 1776-80	1.9	3
508	Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial. <i>Blood Cancer Journal</i> , 2016 , 6, e378	7	39
507	Primary failure of bortezomib in newly diagnosed multiple myeloma--understanding the magnitude, predictors, and significance. <i>Leukemia and Lymphoma</i> , 2016 , 57, 1382-8	1.9	5
506	Neutrophil Gelatinase--Associated Lipocalin and Cystatin C Are Sensitive Markers of Renal Injury in Patients With Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016 , 16, 29-35	2	12
505	Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group. <i>Leukemia</i> , 2016 , 30, 1005-17	10.7	159
504	Health resource utilization associated with skeletal-related events: results from a retrospective European study. <i>European Journal of Health Economics</i> , 2016 , 17, 711-21	3.6	14
503	Distinct Immunogenetic Signatures in IgA Versus IgG Multiple Myeloma. <i>Blood</i> , 2016 , 128, 2062-2062	2.2	3
502	Selective HDAC6 Inhibitor ACY-241, an Oral Tablet, Combined with Pomalidomide and Dexamethasone: Safety and Efficacy of Escalation and Expansion Cohorts in Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma (ACE-MM-200 Study). <i>Blood</i> , 2016 , 128, 3307-3307	2.2	15
501	Pomalidomide with Low Dose Dexamethasone Is Effective Irrespective of Primary or Secondary Resistance to Lenalidomide but the IMiD-Free Interval Is Important. <i>Blood</i> , 2016 , 128, 3310-3310	2.2	1
500	Evaluation of Experimental Retreatment and Prolonged Therapy with Subcutaneous (SC) Bortezomib in Patients (Pts) with Multiple Myeloma in First or Second Relapse, a Randomized, Controlled, Phase 3 Study. <i>Blood</i> , 2016 , 128, 3328-3328	2.2	1
499	Findings of Whole Body Computed Tomography Compared to Conventional Skeletal Survey in Patients with Monoclonal Plasma Cell Disorders - a Study of the International Myeloma Working Group. <i>Blood</i> , 2016 , 128, 4468-4468	2.2	9
498	Cardiac and Renal Complications of Carfilzomib Therapy in Patients with Multiple Myeloma. <i>Blood</i> , 2016 , 128, 4491-4491	2.2	2
497	Growth Differentiation Factor-15 (GDF-15) Is a New Biomarker with Independent Prognostic Significance for Survival and Renal Outcomes in Different Cohorts of Patients with Light Chain (AL) Amyloidosis. <i>Blood</i> , 2016 , 128, 648-648	2.2	1
496	The Role of Imaging in the Treatment of Patients With Multiple Myeloma in 2016. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016 , 36, e407-e417	7.1	19
495	Glomerular expression of matrix metalloproteinases in AL-amyloidosis and association with renal function at the time of kidney biopsy. <i>Clinical Nephrology</i> , 2016 , 85, 44-54	2.1	6
494	Circulating Adiponectin and Markers of Endothelial and Cardiovascular Dysfunction Correlate with Disease Burden in Newly Diagnosed Patients with Multiple Myeloma; Increase of Adiponectin after Bortezomib- and IMiD-Based Regimens. <i>Blood</i> , 2016 , 128, 4446-4446	2.2	
493	Lenalidomide, Adriamycin, and Dexamethasone (RAD) As Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma Who Are Eligible for Autologous Transplantation (ASCT): A Phase 2 Study from the Greek Myeloma Study Group. <i>Blood</i> , 2016 , 128, 4488-4488	2.2	

492	Survivorship in WM: Identification of Factors Associated with Survival of More Than a Decade and with Early WM-Related Death. <i>Blood</i> , 2016 , 128, 2954-2954	2.2	
491	Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG Study. <i>Blood</i> , 2016 , 128, 4414-4414	2.2	
490	Indirubins: A Potential Therapeutic Target in Multiple Myeloma. <i>Blood</i> , 2016 , 128, 3259-3259	2.2	
489	Global, Prospective, Non-Interventional, Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Patients: The Insight-MM Study. <i>Blood</i> , 2016 , 128, 5681-5681	2.2	
488	Real-World Data on Clinical Characteristics, Prognosis and Outcome of Primary Plasma Cell Leukemia: A Study of the Greek Myeloma Study Group in the Era of Novel Agents. <i>Blood</i> , 2016 , 128, 4490-4490	2.2	
487	Addition of Cyclophosphamide and Higher Doses of Dexamethasone Do Not Improve Outcomes of Patients with AL Amyloidosis Treated with Bortezomib. <i>Blood</i> , 2016 , 128, 4500-4500	2.2	
486	The Growth Differentiation Factor-15 Levels Are Increased in Patients with Compound Heterozygous Sickle Cell and Beta-Thalassemia, Correlate with Hepcidin-25/Ferritin Molar Ratio and with Markers of Hemolysis, Endothelial Dysfunction and Angiogenesis. <i>Blood</i> , 2016 , 128, 3646-3646	2.2	
485	Outcomes of Newly Diagnosed Myeloma Patients Requiring Dialysis: Dialysis Independence Is Associated with Rapid Myeloma Response and Predicts for Longer Survival. <i>Blood</i> , 2016 , 128, 4492-4492	2.2	
484	Chromatin Histone Modifying and DNA Repair Inhibition Enhances the Anti-Myeloma Activity of Melphalan. <i>Blood</i> , 2016 , 128, 4437-4437	2.2	
483	The Role of Imaging in the Treatment of Patients With Multiple Myeloma in 2016. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016 , 35, e407-17	7.1	29
482	Clinical vertebral fractures following denosumab discontinuation. <i>Endocrine</i> , 2016 , 54, 271-272	4	28
481	Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis. <i>American Journal of Hematology</i> , 2016 , 91, 499-502	7.1	52
480	A review of the venous thrombotic issues associated with multiple myeloma. <i>Expert Review of Hematology</i> , 2016 , 9, 695-706	2.8	16
479	Emerging antibodies for the treatment of multiple myeloma. <i>Expert Opinion on Emerging Drugs</i> , 2016 , 21, 225-37	3.7	22
478	Cytogenetics and Survival of Multiple Myeloma: Isolated and Combined Effects. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016 , 16, 335-40	2	12
477	DNA repair of myeloma plasma cells correlates with clinical outcome: the effect of the nonhomologous end-joining inhibitor SCR7. <i>Blood</i> , 2016 , 128, 1214-25	2.2	24
476	Discovery and Optimization of a Selective Ligand for the Switch/Sucrose Nonfermenting-Related Bromodomains of Polybromo Protein-1 by the Use of Virtual Screening and Hydration Analysis. <i>Journal of Medicinal Chemistry</i> , 2016 , 59, 8787-8803	8.3	32
475	Pathologic fracture and healthcare resource utilisation: A retrospective study in eight European countries. <i>Journal of Bone Oncology</i> , 2016 , 5, 185-193	4.5	6

474	High levels of periostin correlate with increased fracture rate, diffuse MRI pattern, abnormal bone remodeling and advanced disease stage in patients with newly diagnosed symptomatic multiple myeloma. <i>Blood Cancer Journal</i> , 2016 , 6, e482	7	15
473	TLR4/TIRAP polymorphisms are associated with progression and survival of patients with symptomatic myeloma. <i>British Journal of Haematology</i> , 2016 , 172, 44-7	4.5	5
472	Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement. <i>Journal of Clinical Oncology</i> , 2015 , 33, 657-64	2.2	262
471	An update on the use of lenalidomide for the treatment of multiple myeloma. <i>Expert Opinion on Pharmacotherapy</i> , 2015 , 16, 1865-77	4	8
470	Therapy-related myelodysplastic syndrome/acute leukemia after multiple myeloma in the era of novel agents. <i>Leukemia and Lymphoma</i> , 2015 , 56, 1723-6	1.9	14
469	Involvement of osteocytes in cancer bone niche 2015 , 65-72		1
468	Evaluation of bone involvement in patients with Gaucher disease: a semi-quantitative magnetic resonance imaging method (using ROI estimation of bone lesion) as an alternative method to semi-quantitative methods used so far. <i>European Journal of Haematology</i> , 2015 , 95, 342-51	3.8	5
467	Osteoprotegerin is a significant prognostic factor for overall survival in patients with primary systemic amyloidosis independent of the Mayo staging. <i>Blood Cancer Journal</i> , 2015 , 5, e319	7	11
466	European Myeloma Network guidelines for the management of multiple myeloma-related complications. <i>Haematologica</i> , 2015 , 100, 1254-66	6.6	222
465	Bone antiresorptive agents in the treatment of bone metastases associated with solid tumours or multiple myeloma. <i>BoneKEy Reports</i> , 2015 , 4, 744		12
464	Lack of survival improvement with novel anti-myeloma agents for patients with multiple myeloma and central nervous system involvement: the Greek Myeloma Study Group experience. <i>Annals of Hematology</i> , 2015 , 94, 2033-42	3	34
463	Clinical characteristics of patients with relapsed multiple myeloma. <i>Cancer Treatment Reviews</i> , 2015 , 41, 827-35	14.4	26
462	Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies. <i>American Journal of Hematology</i> , 2015 , 90, E60-5	7.1	45
461	Impact of maintenance therapy on subsequent treatment in patients with newly diagnosed multiple myeloma: use of "progression-free survival 2" as a clinical trial end-point. <i>Haematologica</i> , 2015 , 100, e328-30	6.6	23
460	Competing risk survival analysis in patients with symptomatic Waldenström macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy. <i>Haematologica</i> , 2015 , 100, e446-9	6.6	31
459	Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. <i>Blood</i> , 2015 , 125, 2068-74	2.2	426
458	Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: final analysis of a phase 2 study. <i>Blood</i> , 2015 , 126, 1392-4	2.2	67
457	Alcohol intake, alcoholic beverage type and multiple myeloma risk: a meta-analysis of 26 observational studies. <i>Leukemia and Lymphoma</i> , 2015 , 56, 1484-501	1.9	6

456	The State of Chromatin Condensation, the Expression of Genes Involved in DNA Damage Response and the DNA Repair Capacity Affect the Drug Sensitivity of PBMcs of Myeloma Patients Treated with Melphalan. <i>Blood</i> , 2015 , 126, 3628-3628	2.2	2
455	Diffusion-Weighted Imaging Improves Accuracy in the Diagnosis of MRI Patterns of Marrow Involvement in Newly Diagnosed Myeloma: Results of a Prospective Study in 99 Patients. <i>Blood</i> , 2015 , 126, 4178-4178	2.2	11
454	Outcomes after Initial Relapse of Multiple Myeloma: An International Myeloma Working Group Study. <i>Blood</i> , 2015 , 126, 4201-4201	2.2	3
453	Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, Combines Safely with Pomalidomide and Dexamethasone and Shows Promising Early Results in Relapsed-and-Refractory Myeloma (ACE-MM-102 Study). <i>Blood</i> , 2015 , 126, 4228-4228	2.2	17
452	Bone disease 2015 , 79-90		
451	Denosumab compared with zoledronic acid for the treatment of bone disease in adults with newly diagnosed multiple myeloma: An international, randomized, double-blind trial.. <i>Journal of Clinical Oncology</i> , 2015 , 33, TPS8611-TPS8611	2.2	
450	The Simultaneous Accumulation of the Extremely Cytotoxic Interstrand Cross-Links and Double-Strand Breaks Contributes to the Successful Anti-Myeloma Therapy; The Effect of DNA Repair Inhibitors. <i>Blood</i> , 2015 , 126, 4177-4177	2.2	
449	Bortezomib-Based Triplets Are Associated with a High Probability of Dialysis Independence and Rapid Renal Recovery in Newly Diagnosed Myeloma Patients with Severe Renal Failure or Those Requiring Dialysis. <i>Blood</i> , 2015 , 126, 1832-1832	2.2	
448	Analysis of Molecular-Cellular Responses to Proteasome Inhibitors in Multiple Myeloma Patients; A Translational Approach of Proteasome Inhibitors In Vivo Effects from the Drosophila Experimental Model to Humans. <i>Blood</i> , 2015 , 126, 3250-3250	2.2	
447	Iron Overload of the Kidneys of Patients with Thalassemia and Sickle-Cell Disease: Final Results of a Prospective Study in 224 Patients Using Magnetic Resonance Imaging T2 and R2* Techniques. <i>Blood</i> , 2015 , 126, 2157-2157	2.2	1
446	Analysis of Final Data from the Multinational, Non-Interventional, Observational Emmos Study (NCT01241396) in Patients (Pts) with Multiple Myeloma (MM) in Real-World Clinical Practice. <i>Blood</i> , 2015 , 126, 3034-3034	2.2	1
445	The Role of RANKL/Osteoprotegerin and Wnt Signaling Pathways in the Development of Osteoporosis in Patients with Hemophilia. <i>Blood</i> , 2015 , 126, 2284-2284	2.2	
444	Time to Spare Newly Diagnosed Non Transplant Eligible Myeloma (eNDMM) from Thalidomide. <i>Blood</i> , 2015 , 126, 4245-4245	2.2	
443	Evaluation of the Revised International Staging System (R-ISS) in an Independent Cohort of Unselected Patients with Multiple Myeloma. <i>Blood</i> , 2015 , 126, 3045-3045	2.2	
442	Prospective Evaluation of Blood Pressure Monitoring and Baroreceptor Reflex Sensitivity (BRS) in Patients with AL Amyloidosis: Prognostic and Pathophysiologic Implications. <i>Blood</i> , 2015 , 126, 3054-3054 ²	2.2	
441	Validation of the Novel Criteria for the Definition of Symptomatic Myeloma: A Single Center Experience in 216 Patients with the Previous Diagnosis of Asymptomatic Disease. <i>Blood</i> , 2015 , 126, 4251-4251 ²	2.2	
440	Newly Diagnosed Multiple Myeloma Is Associated with Enhanced TF Pathway Activation, Thrombin Generation and Increased Concentration of Procoagulant Microparticles. <i>Blood</i> , 2015 , 126, 1074-1074	2.2	
439	Characterization of a PERK Kinase Inhibitor with Anti-Myeloma Activity. <i>Blood</i> , 2015 , 126, 4188-4188	2.2	1

438	Real-World Prospective Evaluation of Different Geriatric Assessment Tools in Unselected Elderly Patients with Symptomatic Myeloma. <i>Blood</i> , 2015 , 126, 4242-4242	2.2	
437	Preserved levels of uninvolved immunoglobulins are independently associated with favorable outcome in patients with symptomatic multiple myeloma. <i>Leukemia</i> , 2014 , 28, 2075-9	10.7	44
436	Sotatercept in patients with osteolytic lesions of multiple myeloma. <i>British Journal of Haematology</i> , 2014 , 165, 814-23	4.5	92
435	Hemodynamic markers and subclinical atherosclerosis in postmenopausal women with primary hyperparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014 , 99, 2704-11	5.6	16
434	International Myeloma Working Group recommendations for global myeloma care. <i>Leukemia</i> , 2014 , 28, 981-92	10.7	132
433	Whole-body low-dose computed tomography and advanced imaging techniques for multiple myeloma bone disease. <i>Clinical Cancer Research</i> , 2014 , 20, 5888-97	12.9	55
432	The prognostic importance of the presence of more than one focal lesion in spine MRI of patients with asymptomatic (smoldering) multiple myeloma. <i>Leukemia</i> , 2014 , 28, 2402-3	10.7	93
431	International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. <i>Lancet Oncology</i> , 2014 , 15, e538-48	21.7	2253
430	Hematologic response and stabilization of renal function in a patient with light chain deposition disease after lenalidomide treatment: a novel therapeutic approach?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014 , 14, e179-81	2	6
429	The effects of bortezomib on bone disease in patients with multiple myeloma. <i>Cancer</i> , 2014 , 120, 618-23	6.4	47
428	The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: final results on 205 patients of the Greek myeloma study group. <i>American Journal of Hematology</i> , 2014 , 89, 34-40	7.1	29
427	Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: a report of the Greek myeloma study group in 97 patients. <i>American Journal of Hematology</i> , 2014 , 89, 803-8	7.1	44
426	Management of bone disease in multiple myeloma. <i>Expert Review of Hematology</i> , 2014 , 7, 113-25	2.8	73
425	Baseline osteocalcin levels and incident diabetes in a 3-year prospective study of high-risk individuals. <i>Diabetes and Metabolism</i> , 2014 , 40, 198-203	5.4	15
424	Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents. <i>Annals of Oncology</i> , 2014 , 25, 195-200	10.3	102
423	Less strength and more fractures for MGUS bones. <i>Blood</i> , 2014 , 123, 603-4	2.2	2
422	Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus. <i>Blood</i> , 2014 , 124, 1404-11	2.2	107
421	AB0047 Cd55 Red-Cell Expression in Systemic Autoimmune Disease Reflects Its Impact on Erythropoiesis through Immune-Mediated Bone Marrow Insufficiency. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 819.3-819	2.4	

420	Conservative treatment of bisphosphonate-related osteonecrosis of the jaw in multiple myeloma patients. <i>International Journal of Dentistry</i> , 2014 , 2014, 427273	1.9	18
419	The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network. <i>Haematologica</i> , 2014 , 99, 984-96	6.6	86
418	Lenalidomide in patients with POEMS syndrome: a systematic review and pooled analysis. <i>Leukemia and Lymphoma</i> , 2014 , 55, 2018-23	1.9	45
417	Progressive changes in chromatin structure and DNA damage response signals in bone marrow and peripheral blood during myelomagenesis. <i>Leukemia</i> , 2014 , 28, 1113-21	10.7	8
416	VTD consolidation, without bisphosphonates, reduces bone resorption and is associated with a very low incidence of skeletal-related events in myeloma patients post ASCT. <i>Leukemia</i> , 2014 , 28, 928-34	10.7	31
415	Circulating periostin levels do not differ between postmenopausal women with normal and low bone mass and are not affected by zoledronic acid treatment. <i>Hormone and Metabolic Research</i> , 2014 , 46, 145-9	3.1	22
414	European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. <i>Haematologica</i> , 2014 , 99, 232-42	6.6	146
413	Immunoglobulin D myeloma: clinical features and outcome in the era of novel agents. <i>European Journal of Haematology</i> , 2014 , 92, 308-12	3.8	22
412	Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group. <i>American Journal of Hematology</i> , 2014 , 89, 145-50	7.1	48
411	Pregnancy in beta-thalassemia intermedia: 20-year experience of a Greek thalassemia center. <i>European Journal of Haematology</i> , 2014 , 93, 492-9	3.8	22
410	Biology and management of myeloma-related bone disease. <i>Acta Haematologica Polonica</i> , 2014 , 45, 107-111	1.1	1
409	"Real-world" data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group. <i>Annals of Hematology</i> , 2014 , 93, 129-39	3	36
408	Increased Von Willebrand Factor and High Circulating Placental Growth Factor Correlate with Inflammation and Iron Overload in Patients with Compound Heterozygous Sickle Cell and Beta-Thalassemia. <i>Blood</i> , 2014 , 124, 1392-1392	2.2	2
407	Hypercalcemia Remains an Adverse Prognostic Factor for Newly Diagnosed Patients with Symptomatic Multiple Myeloma in the Era of Novel Anti-Myeloma Therapies, Independently of Age, ISS Stage and Treatment Type: An Analysis of 2129 Patients. <i>Blood</i> , 2014 , 124, 2113-2113	2.2	2
406	Growth Differentiation Factor-15 in Patients with Light Chain (AL) Amyloidosis Has Independent Prognostic Significance and Adds Prognostic Information Related to Risk of Early Death and Renal Outcomes. <i>Blood</i> , 2014 , 124, 306-306	2.2	4
405	Myeloma in the Octogenarians: Disease Characteristics and Clinical Outcomes in the Era of Modern Anti-Myeloma Therapy. <i>Blood</i> , 2014 , 124, 4738-4738	2.2	3
404	Three Drug Combinations Based on Bortezomib and Dexamethasone (VD) Backbone Improve Renal Function More Efficiently Than VD in Myeloma Patients with Severe Renal Impairment. <i>Blood</i> , 2014 , 124, 4769-4769	2.2	1
403	The presence of CD55- and/or CD59-deficient erythrocytic populations in patients with rheumatic diseases reflects an immune-mediated bone-marrow derived phenomenon. <i>Medical Science Monitor</i> , 2014 , 20, 123-39	3.2	9

402	Time to Spare Newly Diagnosed Non Transplant Eligible Myeloma from Thalidomide. <i>Blood</i> , 2014 , 124, 5702-5702	2.2	
401	High Bone Turnover Is Present in Patients with Primary Systemic (AL) Amyloidosis and Increased Osteoprotegerin Identifies Patients with Poor Survival within Mayo Stage 1 Disease. <i>Blood</i> , 2014 , 124, 2028-2028	2.2	
400	Subcutaneous Bortezomib, Melphalan and Prednisone in Elderly Newly Diagnosed Multiple Myeloma Patients. <i>Blood</i> , 2014 , 124, 3481-3481	2.2	
399	No Survival Improvement for Central Nervous System Multiple Myeloma By the Use of Novel Anti-Myeloma Agents: The Greek Myeloma Study Group Experience. <i>Blood</i> , 2014 , 124, 4752-4752	2.2	
398	Hemodynamic, Functional and Structural Markers of Vascular Involvement in Primary Systemic Light Chain (AL) Amyloidosis. <i>Blood</i> , 2014 , 124, 2029-2029	2.2	
397	The Combination of Bortezomib and Lenalidomide (VR) Consolidation Post-ASCT, in the Absence of Dexamethasone and Bisphosphonates, Improves Response Rates and Bone Metabolism in Newly Diagnosed Patients with Multiple Myeloma. <i>Blood</i> , 2014 , 124, 3462-3462	2.2	
396	Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI) Is Able to Distinguish Diffuse from Normal MRI Pattern of Marrow Involvement in Patients with Multiple Myeloma. <i>Blood</i> , 2014 , 124, 3461-3461	2.2	0
395	Amplification of 1q21 Is Associated with Other High Risk Cytogenetic Abnormalities and Has No Independent Prognostic Significance in Patients Treated with Novel Agents. <i>Blood</i> , 2014 , 124, 3464-3464	2.2	
394	Renal Outcomes in Patients with AL Amyloidosis: Evaluation of Prognostic Factors and Impact of Therapy with Novel Agents. <i>Blood</i> , 2014 , 124, 2130-2130	2.2	
393	Genetic Factors Related with Early Onset of Osteonecrosis of the Jaw in Patients with Multiple Myeloma Under Zoledronic Acid Therapy. <i>Blood</i> , 2014 , 124, 2115-2115	2.2	
392	Translating Findings of Proteasome Inhibitors Effects from the in Vivo <i>Drosophila</i> Experimental Model to Humans: The Paradigm of the Molecular-Cellular Responses to Bortezomib and Carfilzomib. <i>Blood</i> , 2014 , 124, 4814-4814	2.2	
391	Circulating Adamts-13 Is Reduced in Patients with Waldenstrom's Macroglobulinemia and Is Associated with Increased IgM Levels and Features of the Disease but Not with the Increased Levels of Von Willebrand Factor. <i>Blood</i> , 2014 , 124, 5741-5741	2.2	
390	Circulating activin-A is elevated in postmenopausal women with low bone mass: the three-month effect of zoledronic acid treatment. <i>Osteoporosis International</i> , 2013 , 24, 2127-32	5.3	11
389	Decreased incidence of EPCR 4678G/C SNP in multiple myeloma patients with thrombosis. <i>Thrombosis Research</i> , 2013 , 132, 400-1	8.2	4
388	Effects of proteasome inhibitors on bone cancer. <i>BoneKEy Reports</i> , 2013 , 2, 395		15
387	International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2347-57	2.2	245
386	Proteasome dysfunction in <i>Drosophila</i> signals to an Nrf2-dependent regulatory circuit aiming to restore proteostasis and prevent premature aging. <i>Aging Cell</i> , 2013 , 12, 802-13	9.9	86
385	Current treatments for renal failure due to multiple myeloma. <i>Expert Opinion on Pharmacotherapy</i> , 2013 , 14, 1477-95	4	27

384	Imatinib and chronic myeloid leukemia: close to the bone. <i>Leukemia and Lymphoma</i> , 2013 , 54, 1581-2	1.9	
383	Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma. <i>Blood</i> , 2013 , 121, 318-28	2.2	100
382	A novel noninvasive index for nonalcoholic steatohepatitis: a pilot study. <i>Biomarkers</i> , 2013 , 18, 607-13	2.6	14
381	Response assessment in Waldenström macroglobulinaemia: update from the Vth International Workshop. <i>British Journal of Haematology</i> , 2013 , 160, 171-6	4.5	173
380	Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease. <i>Leukemia</i> , 2013 , 27, 947-53	10.7	113
379	Possible survival benefits from zoledronic acid treatment in patients with bone metastases from solid tumours and poor prognostic features-An exploratory analysis of placebo-controlled trials. <i>Journal of Bone Oncology</i> , 2013 , 2, 70-6	4.5	30
378	Helicobacter pylori infection in patients with nonalcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2013 , 62, 121-6	12.7	97
377	The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma. <i>Leukemia</i> , 2013 , 27, 423-9	10.7	105
376	Activin receptor antagonists for cancer-related anemia and bone disease. <i>Expert Opinion on Investigational Drugs</i> , 2013 , 22, 87-101	5.9	54
375	Correlation of Fc-γRIIA polymorphisms with latent Epstein-Barr virus infection and latent membrane protein 1 expression in patients with low grade B-cell lymphomas. <i>Leukemia and Lymphoma</i> , 2013 , 54, 2030-4	1.9	16
374	Serum sclerostin levels following treatment with parathyroid hormone. <i>Journal of Endocrinological Investigation</i> , 2013 , 36, 280	5.2	1
373	Re-evaluation of prognostic markers including staging, serum free light chains or their ratio and serum lactate dehydrogenase in multiple myeloma patients receiving novel agents. <i>Hematological Oncology</i> , 2013 , 31, 96-102	1.3	44
372	Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma. <i>OncoTargets and Therapy</i> , 2013 , 6, 531-8	4.4	25
371	Tobacco smoking and risk of multiple myeloma: a meta-analysis of 40 observational studies. <i>International Journal of Cancer</i> , 2013 , 132, 2413-31	7.5	17
370	Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens. <i>American Journal of Hematology</i> , 2013 , 88, 765-70	7.1	26
369	The Chronic Kidney Disease Epidemiology Collaboration cystatin C (CKD-EPI-CysC) equation has an independent prognostic value for overall survival in newly diagnosed patients with symptomatic multiple myeloma; is it time to change from MDRD to CKD-EPI-CysC equations?. <i>European Journal of Haematology</i> , 2013 , 91, 347-55	3.8	31
368	Comparison of modern and conventional imaging techniques in establishing multiple myeloma-related bone disease: a systematic review. <i>British Journal of Haematology</i> , 2013 , 162, 50-61	4.5	139
367	Optimal use of bisphosphonates in patients with multiple myeloma. <i>Blood</i> , 2013 , 121, 3325-8	2.2	34

366	Elevated Von Willebrand Factor Antigen Serum Levels Are Associated With Poor Prognosis In Patients With Symptomatic Waldenström Macroglobulinemia. <i>Blood</i> , 2013 , 122, 1860-1860	2.2	2
365	Vascular Cell Adhesion Molecule-1 Is An Independent Prognostic Factor For Newly-Diagnosed Patients With Multiple Myeloma; Reductions Post VD and Rd In Myeloma Patients At First Relapse. <i>Blood</i> , 2013 , 122, 1916-1916	2.2	1
364	The Novel Proteasome Inhibitors Carfilzomib and Oprozomib Induce Milder Degenerative Effects Compared To Bortezomib When Administered Via Oral Feeding In An In Vivo Drosophila Experimental Model: A Biological Platform To Evaluate Safety/Efficacy Of Proteasome Inhibitors. <i>Blood</i> , 2013 , 122, 1930-1930	2.2	1
363	IgD Myeloma: Clinical Features and Outcome In The Era Of Novel Agents. <i>Blood</i> , 2013 , 122, 1935-1935	2.2	1
362	Molecular Analyses Of The Effects Induced By Orally Administered Bortezomib In Drosophila Flies: A Novel In Vivo Experimental Platform To Screen For The Tissue- and Age-Dependent Effects Of Proteasome Inhibitors. <i>Blood</i> , 2013 , 122, 2910-2910	2.2	1
361	Skeletal-Related Events In Patients With Multiple Myeloma In The Era Of Novel Agents: Low Incidence Of Pathological Fractures After Treatment. <i>Blood</i> , 2013 , 122, 3090-3090	2.2	2
360	Toll-Like Receptor Activation Promotes Multiple Myeloma Cell Growth and Survival By Suppression Of Endoplasmic Reticulum Stress Factor CHOP. <i>Blood</i> , 2013 , 122, 3112-3112	2.2	1
359	Very Early Death (. <i>Blood</i> , 2013 , 122, 3195-3195	2.2	3
358	The Cumulative Dose But Not The Frequency Of Infusions Is a Risk Factor For The Development Of Osteonecrosis Of The Jaw (ONJ) In Myeloma Patients Who Receive Zoledronic Acid (ZA). <i>Blood</i> , 2013 , 122, 3196-3196	2.2	1
357	Circulating Periostin Is Elevated In Patients With Hemoglobinopathies and Correlates With Bone Mineral Density In Double Heterozygous Sickle-Cell/Beta-Thalassemia Patients; A Novel Marker Of Bone Strength?. <i>Blood</i> , 2013 , 122, 3445-3445	2.2	1
356	Evaluating results from the multiple myeloma subset of patients treated with denosumab or zoledronic acid (ZA) in a randomized phase III study.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 8589-8589	2.2	1
355	Angiogenic cytokines profile in smoldering multiple myeloma: no difference compared to MGUS but altered compared to symptomatic myeloma. <i>Medical Science Monitor</i> , 2013 , 19, 1188-94	3.2	6
354	The Effect of Novel Anti-myeloma Agents on Bone Metabolism 2013 , 257-275		
353	The CKD-EPI-Cystatin C Equation For The Estimation Of Glomerular Filtration Rate Detects Higher Number Of Patients With Thalassemia Major and Renal Impairment, Before and After Treatment With Deferasirox; Is It Time To Change From MDRD To CKD-EPI-Cystatin C equation In Thalassemia? <i>Blood</i> , 2013 , 122, 3451-3451	2.2	
352	Validation Of Criteria For Renal Response In Patients With Multiple Myeloma (MM) Who Present With Severe Renal Dysfunction. <i>Blood</i> , 2013 , 122, 3176-3176	2.2	
351	Estimated Glomerular Filtration Rate Calculated By The CKD-EPI Formula Has Improved Prognostic Ability Over MDRD Formula In Patients With Newly Diagnosed, Symptomatic, Multiple Myeloma: Analysis In 1937 Patients. <i>Blood</i> , 2013 , 122, 1867-1867	2.2	1
350	Disease-Associated Changes In The Repair Efficiency Of Double Strand Breaks Affect Melphalan Sensitivity Of The Bone Marrow Plasma Cells and Correlate With The Clinical Outcome Of Anti-Myeloma Therapy. <i>Blood</i> , 2013 , 122, 3723-3723	2.2	0
349	Competing Risk Survival Analysis In Patients With Symptomatic Waldenström Macroglobulinemia (WM): Disease Unrelated Mortality Accounts For Differences In Survival In Patients >75 Years. <i>Blood</i> , 2013 , 122, 3197-3197	2.2	

348	Preserved Levels Of Uninvolved Immunoglobulins Are Associated With Better Overall Survival In Patients With Multiple Myeloma Independently Of Disease Burden: A Role For The Immune System?. <i>Blood</i> , 2013 , 122, 1866-1866	2.2	
347	Genetic Variations In TLR-4/TIRAP Genes Influence Response To IMiDs-Based Regimens and Conventional Chemotherapy In Patients With Multiple Myeloma. <i>Blood</i> , 2013 , 122, 1861-1861	2.2	
346	Tubular Damage Is Present In Patients With MGUS and Asymptomatic Multiple Myeloma Even In The Absence Of Impaired Estimated Glomerular Filtration Rate; Alterations Of Neutrophil Gelatinase-Associated Lipocalin and Cystatin-C In Myeloma Patients Post IMiD- and Bortezomib-Based Regimens. <i>Blood</i> , 2013 , 122, 3091-3091	2.2	
345	Clinical Features, Outcome and Prognostic Factors For Survival and Evolution To Multiple Myeloma Of Solitary Plasmacytomas: A Report Of The Greek Myeloma Study Group In 97 Patients. <i>Blood</i> , 2013 , 122, 3130-3130	2.2	
344	Multiple Myeloma Patients \geq 40 Years Of Age: Clinical Characteristics and Outcome In The Era Of Novel Agents. <i>Blood</i> , 2013 , 122, 3226-3226	2.2	
343	Elevated Serum Levels Of Von Willebrand Factor (vWF) Predict For Early Death and Shorter Survival In Patients With Primary Systemic Light Chain (AL) Amyloidosis Independently Of Cardiac Biomarkers. <i>Blood</i> , 2013 , 122, 3194-3194	2.2	
342	Presence Of CD55- and/Or CD59-Deficient Erythrocytes In Patients With Rheumatic Diseases: An Immune-Mediated Phenomenon?. <i>Blood</i> , 2013 , 122, 3429-3429	2.2	
341	Lenalidomide Administration In Patients With POEMS Syndrome. <i>Blood</i> , 2013 , 122, 3235-3235	2.2	1
340	Adipocytokines and cytokeratin-18 in patients with nonalcoholic fatty liver disease: Introduction of CHA index. <i>Annals of Hepatology</i> , 2013 , 12, 749-57	3.1	9
339	Multiple myeloma in octogenarians: clinical features and outcome in the novel agent era. <i>European Journal of Haematology</i> , 2012 , 89, 10-5	3.8	25
338	Sickle-cell disease and the heart: review of the current literature. <i>British Journal of Haematology</i> , 2012 , 157, 664-73	4.5	50
337	Circulating angiopoietin-1 to angiopoietin-2 ratio is an independent prognostic factor for survival in newly diagnosed patients with multiple myeloma who received therapy with novel antimyeloma agents. <i>International Journal of Cancer</i> , 2012 , 130, 735-42	7.5	23
336	VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor Type 2. <i>International Journal of Cancer</i> , 2012 , 130, 857-64	7.5	96
335	Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women--the six-month effect of risedronate and teriparatide. <i>Osteoporosis International</i> , 2012 , 23, 1171-6	5.3	98
334	A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis. <i>Blood</i> , 2012 , 119, 5384-90	2.2	77
333	The International Scoring System (ISS) for multiple myeloma remains a robust prognostic tool independently of patients' renal function. <i>Annals of Oncology</i> , 2012 , 23, 722-729	10.3	20
332	Sclerostin: a possible target for the management of cancer-induced bone disease. <i>Expert Opinion on Therapeutic Targets</i> , 2012 , 16, 761-9	6.4	27
331	Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. <i>Leukemia</i> , 2012 , 26, 149-57	10.7	580

330	Impact of bortezomib on bone health in myeloma: a review of current evidence. <i>Cancer Treatment Reviews</i> , 2012 , 38, 968-80	14.4	38
329	Treatment with lenalidomide and dexamethasone in patients with multiple myeloma and renal impairment. <i>Cancer Treatment Reviews</i> , 2012 , 38, 1012-9	14.4	13
328	Prevention and treatment of myeloma bone disease. <i>Current Hematologic Malignancy Reports</i> , 2012 , 7, 249-57	4.4	10
327	New Insights in Waldenström Macroglobulinemia 2012 , 223-236		
326	Management of treatment-emergent peripheral neuropathy in multiple myeloma. <i>Leukemia</i> , 2012 , 26, 595-608	10.7	189
325	Increased angiogenesis and enhanced bone formation in patients with IgM monoclonal gammopathy and urticarial skin rash: new insight into the biology of Schnitzler syndrome. <i>Haematologica</i> , 2012 , 97, 1699-703	6.6	24
324	Reduced bone mineral density in adult patients with Langerhans cell histiocytosis. <i>Pediatric Blood and Cancer</i> , 2012 , 58, 819-22	3	10
323	Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapy. <i>International Journal of Cancer</i> , 2012 , 131, 1466-71	7.5	131
322	Increased expression of cyclin-D1 on trephine bone marrow biopsies independently predicts for shorter overall survival in patients with multiple myeloma treated with novel agents. <i>American Journal of Hematology</i> , 2012 , 87, 734-6	7.1	6
321	Diffuse pattern of bone marrow involvement on magnetic resonance imaging is associated with high risk cytogenetics and poor outcome in newly diagnosed, symptomatic patients with multiple myeloma: a single center experience on 228 patients. <i>American Journal of Hematology</i> , 2012 , 87, 861-4	7.1	63
320	Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy in primary mediastinal large B-cell lymphoma: the emerging standard of care. <i>Oncologist</i> , 2012 , 17, 239-49	5.7	85
319	Is serum IL-17A a useful systemic biomarker in patients with Langerhans cell histiocytosis?. <i>Molecular Therapy</i> , 2012 , 20, 6-7	11.7	10
318	High circulating sclerostin is present in patients with thalassemia-associated osteoporosis and correlates with bone mineral density. <i>Hormone and Metabolic Research</i> , 2012 , 44, 909-13	3.1	44
317	Serum osteoprotegerin, RANKL, and Dkk-1 levels in adults with Langerhans cell histiocytosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012 , 97, E618-21	5.6	7
316	Bisphosphonate anticancer activity in multiple myeloma. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2012 , 12, 123-8	2.2	7
315	Challenging the current approaches to multiple myeloma- and other cancer-related bone diseases: from bisphosphonates to targeted therapy. <i>Leukemia and Lymphoma</i> , 2012 , 53, 1057-61	1.9	11
314	Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; no alterations post-lenalidomide and dexamethasone therapy. <i>Annals of Oncology</i> , 2012 , 23, 2681-2686	10.3	89
313	VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2. <i>British Journal of Cancer</i> , 2012 , 107, 1869-75	8.7	87

312	Semaphorin-4D and Plexin-B1 Are Elevated in Multiple Myeloma Microenvironment and Possibly Contribute in the Development of Lytic Bone Disease. <i>Blood</i> , 2012 , 120, 1819-1819	2.2	6
311	Tubular Damage Is Ubiquitous in Newly-Diagnosed Patients with Multiple Myeloma: Comparison of Three Urinary and Two Serum Markers of Kidney Injury.. <i>Blood</i> , 2012 , 120, 2919-2919	2.2	3
310	High Levels of Periostin in Patients with Multiple Myeloma Correlate with Low Bone Formation, Increased Fracture Rate and Diffuse MRI Pattern; Implications Into the Biology of Myeloma Bone Disease. <i>Blood</i> , 2012 , 120, 3967-3967	2.2	1
309	Lenalidomide with Low or Intermediate Dose Dexamethasone in Patients with Relapsed or Refractory Myeloma. <i>Blood</i> , 2012 , 120, 4028-4028	2.2	1
308	Primary Treatment of Waldenstrom's Macroglobulinemia with Dexamethasone, Rituximab and Cyclophosphamide (DRC): Final Analysis of a Phase II Study. <i>Blood</i> , 2012 , 120, 438-438	2.2	8
307	Increased Serum Transforming Growth Factor-beta1 (Tgf-beta1) Is Related to a Better Outcome in MM, WM and CLL Patients. <i>Blood</i> , 2012 , 120, 4976-4976	2.2	1
306	Circulating Activin-A Is Elevated in Patients with Thalassemia Major and Double Heterozygous Sickle-Cell/Beta-Thalassemia and Correlates with Markers of Hemolysis and Bone Mineral Density. <i>Blood</i> , 2012 , 120, 3256-3256	2.2	
305	Significant Improvement of the Survival of Patients with Multiple Myeloma Presenting with Severe Renal Impairment After the Introduction of Novel Agents. <i>Blood</i> , 2012 , 120, 948-948	2.2	
304	Survival until First Progression and Post First Progression Survival Equally Contribute to the Overall Survival of Myeloma Patients: Differences in Patients \leq 5 Years of Age Compared to Patients >65 Years. <i>Blood</i> , 2012 , 120, 4030-4030	2.2	
303	The Chronic Kidney Disease-Epidemiology Collaboration-Cystatin C (CKD-EPI-CysC) Equation Has an Independent Prognostic Value for Overall Survival in Newly-Diagnosed Patients with Symptomatic Multiple Myeloma: Comparison with 3 Other Equations for GFR Estimation. <i>Blood</i> , 2012 , 120, 1849-1849	2.2	
302	Lower Levels of Survivin in Patients with Leukemic Low Grade B-Cell Lymphomas Expressing LMP1 Oncoprotein of Epstein-Barr Virus. <i>Blood</i> , 2012 , 120, 1560-1560	2.2	
301	The Role of Angiopoietins System in Waldenstrom's Macroglobulinemia: Correlations with Marrow Microvessel Density and Survival. <i>Blood</i> , 2012 , 120, 3901-3901	2.2	1
300	Outcomes of Primary Systemic Light Chain (AL) Amyloidosis in Patients Treated Upfront with Novel Agents and the Importance of Risk Adapted Treatment Strategies. <i>Blood</i> , 2012 , 120, 1786-1786	2.2	0
299	A Study of the Expression of the LMP1 Oncoprotein in Low-Grade B Cell Lymphomas and Correlation with the Levels of Oxidative Stress. <i>Blood</i> , 2012 , 120, 4833-4833	2.2	
298	High C-Terminal Cross-Linking Telopeptide of Collagen Type-I (CTX) Predicts for Poor Overall Survival in Patients with Multiple Myeloma Who Receive Frontline Therapy with Immunomodulatory Drugs (IMiDs) but Not with Bortezomib-Based Regimens. <i>Blood</i> , 2012 , 120, 935-935	2.2	
297	Replacement Therapy with Imiglucerase Improves Magnetic Resonance Imaging (MRI) Abnormalities in Almost Half Patients with Non-Neuronopathic Form of Gaucher Disease After Twelve Months of Therapy: Results of a Semi-Quantitative MRI Method.. <i>Blood</i> , 2012 , 120, 2132-2132	2.2	
296	Normal bone turnover markers in a patient with active Paget's disease of bone: response to treatment with zoledronic acid. <i>Endokrynologia Polska</i> , 2012 , 63, 312-5	1.1	
295	Increased serum lactate dehydrogenase should be included among the variables that define very-high-risk multiple myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011 , 11, 409-13	2	28

294	Renal impairment is not an independent adverse prognostic factor in patients with multiple myeloma treated upfront with novel agent-based regimens. <i>Leukemia and Lymphoma</i> , 2011 , 52, 2299-303 ^{1,9}	26
293	Expression of CCL3 by neoplastic cells in patients with Waldenström's macroglobulinemia: an immunohistochemical study in bone marrow biopsies of 67 patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011 , 11, 115-7	2 9
292	Advances in the treatment of multiple myeloma. <i>European Journal of Cancer</i> , 2011 , 47 Suppl 3, S306-8	7.5 3
291	Zoledronic acid for all patients with newly diagnosed multiple myeloma?. <i>Lancet Oncology</i> , 2011 , 12, 711-2	21.7
290	Hyperphosphorylated paratarg-7: a new molecularly defined risk factor for monoclonal gammopathy of undetermined significance of the IgM type and Waldenstrom macroglobulinemia. <i>Blood</i> , 2011 , 117, 2918-23	2.2 32
289	Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). <i>Blood</i> , 2011 , 118, 4519-29	2.2 267
288	CYP2C8 gene polymorphism and bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma. <i>Haematologica</i> , 2011 , 96, 1557-9	6.6 27
287	Successful chelation therapy with the combination of deferasirox and deferiprone in a patient with thalassaemia major and persisting severe iron overload after single-agent chelation therapies. <i>British Journal of Haematology</i> , 2011 , 154, 654-6	4.5 34
286	Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma. <i>European Journal of Haematology</i> , 2011 , 86, 372-84	3.8 71
285	Short progression-free survival predicts for poor overall survival in older patients with multiple myeloma treated upfront with novel agent-based therapy. <i>European Journal of Haematology</i> , 2011 , 87, 323-9	3.8 3
284	Increased RANKL and IL-6 levels might result in high bone turnover in a case of a CD34+/CD117+/myeloperoxidase(+dim) acute myeloid leukemia presenting with severe hypercalcemia and lumbar spine fractures. <i>Leukemia Research</i> , 2011 , 35, e188-9	2.7 3
283	Prognostic significance of bone markers in patients with lung cancer metastatic to the skeleton: a review of published data. <i>Clinical Lung Cancer</i> , 2011 , 12, 341-9	4.9 24
282	Consensus on the utility of bone markers in the malignant bone disease setting. <i>Critical Reviews in Oncology/Hematology</i> , 2011 , 80, 411-32	7 72
281	Interaction between the skeletal and immune systems in cancer: mechanisms and clinical implications. <i>Cancer Immunology, Immunotherapy</i> , 2011 , 60, 305-17	7.4 22
280	Deferasirox effectively decreases iron burden in patients with double heterozygous HbS/β-thalassemia. <i>Annals of Hematology</i> , 2011 , 90, 11-5	3 9
279	Zoledronic acid-induced transient hepatotoxicity in a patient effectively treated for Paget's disease of bone. <i>Osteoporosis International</i> , 2011 , 22, 363-7	5.3 14
278	Established role of bisphosphonate therapy for prevention of skeletal complications from myeloma bone disease. <i>Critical Reviews in Oncology/Hematology</i> , 2011 , 77 Suppl 1, S13-23	7 21
277	No significant improvement in the outcome of patients with Waldenström's macroglobulinemia treated over the last 25 years. <i>American Journal of Hematology</i> , 2011 , 86, 479-83	7.1 30

276	Lenalidomide-associated pneumonitis in patients with plasma cell dyscrasias. <i>American Journal of Hematology</i> , 2011 , 86, 882-4	7.1	13
275	Tumor-primed natural killer cells from patients with multiple myeloma lyse autologous, NK-resistant, bone marrow-derived malignant plasma cells. <i>American Journal of Hematology</i> , 2011 , 86, 967-73	7.1	15
274	Serglycin inhibits the classical and lectin pathways of complement via its glycosaminoglycan chains: implications for multiple myeloma. <i>European Journal of Immunology</i> , 2011 , 41, 437-49	6.1	40
273	Advances in imaging and the management of myeloma bone disease. <i>Journal of Clinical Oncology</i> , 2011 , 29, 1907-15	2.2	95
272	Paget's disease of bone and calcium homeostasis: focus on bisphosphonate treatment. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2011 , 119, 519-24	2.3	15
271	Reply to C.A. Hutchison et al. <i>Journal of Clinical Oncology</i> , 2011 , 29, e314-e314	2.2	1
270	Circulating Periostin Is Elevated in Patients with Multiple Myeloma and Correlates with Advanced Disease Features and High Bone Resorption,. <i>Blood</i> , 2011 , 118, 3922-3922	2.2	1
269	Frequency and Prognostic Significance of Hypercalcemia in Patients with Multiple Myeloma: An Analysis of the Database of the Greek Myeloma Study Group. <i>Blood</i> , 2011 , 118, 5083-5083	2.2	3
268	Patients with POEMS Syndrome Have High Bone Turnover and Increased Circulating Angiogenic Cytokines; Should Angiopoietin-2 and Bone-Specific Alkaline Phosphatase Be Used As Minor Criteria for the Diagnosis of the Disease?. <i>Blood</i> , 2011 , 118, 806-806	2.2	1
267	The Role of Novel Agents on Reversibility of Renal Impairment in Newly Diagnosed Patients with Multiple Myeloma; a Single Center Experience on 112 Patients,. <i>Blood</i> , 2011 , 118, 3961-3961	2.2	
266	Clinical Features and Outcome of Newly Diagnosed, Symptomatic Patients with Multiple Myeloma 80 Years of Age: An Analysis of the Greek Myeloma Study Group. <i>Blood</i> , 2011 , 118, 5084-5084	2.2	
265	Characteristics and Clinical Course of Myeloma in Patients 40 Years of Age or Younger: A Study of the Greek Myeloma Study Group. <i>Blood</i> , 2011 , 118, 5085-5085	2.2	
264	Comparison of the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI), Modification of Diet in Renal Disease (MDRD) Study Equations and A Formula Based on Cystatin-C and Serum Creatinine for the Estimation of Glomerular Filtration Rate in Patients with Multiple Myeloma; Is It Time to Change From MDRD to CKD-EPI Equation?. <i>Blood</i> , 2011 , 118, 5091-5091	2.2	
263	Effect of Circulating CCL3, Which Is Produced by Malignant Cells of Waldenstro m's Macroglobulinemia, on Patients' Survival. <i>Blood</i> , 2011 , 118, 2894-2894	2.2	
262	Extensive Bone Marrow Infiltration and Abnormal Free Light Chain Ratio Identifies Patients with Smoldering Myeloma At High Risk for Progression to Symptomatic Disease,. <i>Blood</i> , 2011 , 118, 3926-3926 ^{2.2}		
261	Circulating Angiogenic Cytokines Are Elevated in Patients with Smoldering Myeloma; Implications Into Disease Biology. <i>Blood</i> , 2011 , 118, 5059-5059	2.2	
260	Diffuse Pattern of Bone Marrow Involvement in MRI Is Associated with High Risk Cytogenetics and Poor Outcome in Newly Diagnosed, Symptomatic Patients with Multiple Myeloma,. <i>Blood</i> , 2011 , 118, 3920-3920	2.2	
259	Low Circulating Mannan-Binding Leptin Levels Correlate with Increased Number of Febrile Episodes in Myeloma Patients Who Undergo High Dose Melphalan with Autologous Hematopoietic Stem Cell Transplantation and Do Not Receive Antibiotic Prophylaxis. <i>Blood</i> , 2011 , 118, 4457-4457	2.2	

258	Bone Involvement in Patients with Non-Neuronopathic Gaucher Disease Is Characterized by Increased Osteoclast Function Partially Due to High Circulating C-C Motif Ligand 3. <i>Blood</i> , 2011 , 118, 3215-3215	2.2	
257	Prospective Evaluation of the Risk of Thromboembolic Complications in Patients Treated with Lenalidomide-based Therapy and Genetic Associations. <i>Blood</i> , 2011 , 118, 2872-2872	2.2	
256	Increased Angiogenesis and Enhanced Bone Formation in Patients with IgM Monoclonal Gammopathy and Urticarial Skin Rash: New Insight Into the Biology of the Schnitzler Syndrome. <i>Blood</i> , 2011 , 118, 1802-1802	2.2	
255	Bone Marrow Biopsy May Be Required During the Initial Evaluation of Individuals with Asymptomatic Monoclonal Gammopathy. <i>Blood</i> , 2011 , 118, 5067-5067	2.2	
254	Deletion 17p in Unselected Newly Diagnosed Symptomatic Patients with Multiple Myeloma. <i>Blood</i> , 2011 , 118, 5081-5081	2.2	
253	High Circulating Vascular Endothelial Growth Factor Receptor-1 Correlates with Increased Microvessel Density and Inferior Survival in Newly-Diagnosed Patients with Multiple Myeloma Who Receive Frontline Therapy with Novel Agent-Based Regimens. <i>Blood</i> , 2011 , 118, 5082-5082	2.2	
252	High Frequency of Monoclonal Immunoglobulins Exhibiting Natural Autoantibody-Like Activity in Patients with Multiple Myeloma and Waldenstrom Macroglobulinemia. <i>Blood</i> , 2011 , 118, 2893-2893	2.2	0
251	Effect of Amp5q31 and Del12p13 on Survival of Patients with Multiple Myeloma Treated with Novel Agent-Based Regimens: A Single Center Experience on 172 Patients. <i>Blood</i> , 2011 , 118, 1811-1811	2.2	
250	Mobilization of Autologous Peripheral Blood Stem Cells with Spectra Optia v5.0: A Single Center Experience with An Automatic Interface-Controlled Apheresis System. <i>Blood</i> , 2011 , 118, 4396-4396	2.2	
249	Discovering the Epigenetic Modifications and the Alterations in Cellular DNA Damage Response Pathways That Drive Myelomagenesis; Clinical Implications Into the Biology of Multiple Myeloma. <i>Blood</i> , 2011 , 118, 299-299	2.2	
248	Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Cystatin-C Are Sensitive Markers of Renal Injury in Patients with Multiple Myeloma. <i>Blood</i> , 2011 , 118, 3918-3918	2.2	
247	Early effects of IL-6 receptor inhibition on bone homeostasis: a pilot study in women with rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2011 , 29, 921-5	2.2	46
246	Treatment with deferasirox (Exjade) effectively decreases iron burden in patients with thalassaemia intermedia: results of a pilot study. <i>British Journal of Haematology</i> , 2010 , 148, 332-4	4.5	28
245	High levels of serum angiogenic growth factors in patients with AL amyloidosis: comparisons with normal individuals and multiple myeloma patients. <i>British Journal of Haematology</i> , 2010 , 150, 587-91	4.5	10
244	A European consensus report on blood cell identification: terminology utilized and morphological diagnosis concordance among 28 experts from 17 countries within the European LeukemiaNet network WP10, on behalf of the ELN Morphology Faculty. <i>British Journal of Haematology</i> , 2010 , 151, 359-64	4.5	25
243	The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group. <i>Leukemia</i> , 2010 , 24, 1700-12	10.7	66
242	Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies. <i>Leukemia</i> , 2010 , 24, 1769-78	10.7	98
241	Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease. <i>Leukemia</i> , 2010 , 24, 1043-9	10.7	75

240	Diffuse MRI marrow pattern correlates with increased angiogenesis, advanced disease features and poor prognosis in newly diagnosed myeloma treated with novel agents. <i>Leukemia</i> , 2010 , 24, 1206-12	10.7	57
239	Treatment options for thalassemia patients with osteoporosis. <i>Annals of the New York Academy of Sciences</i> , 2010 , 1202, 237-43	6.5	42
238	Increased bone mineral density in a subset of patients with relapsed multiple myeloma who received the combination of bortezomib, dexamethasone and zoledronic acid. <i>Annals of Oncology</i> , 2010 , 21, 1561-1562	10.3	52
237	Multiple myeloma. <i>Annals of Oncology</i> , 2010 , 21 Suppl 7, vii143-50	10.3	62
236	Renal insufficiency and failure. <i>Hematology American Society of Hematology Education Program</i> , 2010 , 2010, 431-6	3.1	21
235	European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma. <i>Leukemia and Lymphoma</i> , 2010 , 51, 2006-11	1.9	13
234	Dual-energy X-ray absorptiometry and quantitative ultrasound in patients with Paget's disease of bone before and after treatment with zoledronic acid: association with serum bone markers and Dickkopf-1. <i>Journal of Clinical Densitometry</i> , 2010 , 13, 190-6	3.5	3
233	Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. <i>Journal of Clinical Oncology</i> , 2010 , 28, 4976-84	2.2	290
232	Intravenous pamidronate for myeloma bone disease: can the dose be lowered?. <i>Lancet Oncology</i> , 2010 , 11, 913-4	21.7	
231	The effect of teriparatide on serum Dickkopf-1 levels in postmenopausal women with established osteoporosis. <i>Clinical Endocrinology</i> , 2010 , 72, 752-7	3.4	45
230	The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). <i>Blood</i> , 2010 , 115, 2354-63	2.2	311
229	Increased bone resorption is implicated in the pathogenesis of bone loss in hemophiliacs: correlations with hemophilic arthropathy and HIV infection. <i>Annals of Hematology</i> , 2010 , 89, 67-74	3	55
228	Serum homocysteine, folate and vitamin B12 in patients with Paget's disease of bone: the effect of zoledronic acid. <i>Journal of Bone and Mineral Metabolism</i> , 2010 , 28, 314-9	2.9	8
227	Profound hypocalcemia following effective response to zoledronic acid treatment in a patient with juvenile Paget's disease. <i>Journal of Bone and Mineral Metabolism</i> , 2010 , 28, 706-12	2.9	24
226	Serum bone turnover markers may be involved in the metastatic potential of lung cancer patients. <i>Medical Oncology</i> , 2010 , 27, 332-8	3.7	28
225	High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents. <i>European Journal of Haematology</i> , 2010 , 85, 114-9	3.8	82
224	Prophylactic antibiotics for the prevention of neutropenic fever in patients undergoing autologous stem-cell transplantation: results of a single institution, randomized phase 2 trial. <i>American Journal of Hematology</i> , 2010 , 85, 863-7	7.1	39
223	Incorporating novel agents in the treatment of myelodysplastic syndromes. <i>Leukemia Research</i> , 2010 , 34, 6-17	2.7	9

222	High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agents. <i>Leukemia Research</i> , 2010 , 34, 399-402	2.7	20
221	Acute lymphoplasmacytoid dendritic cell (DC2) leukemia: results from the Hellenic Dendritic Cell Leukemia Study Group. <i>Leukemia Research</i> , 2010 , 34, 438-46	2.7	77
220	Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom's macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH). <i>Leukemia Research</i> , 2010 , 34, 1340-3	2.7	45
219	Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents. <i>Leukemia Research</i> , 2010 , 34, 1395-7	2.7	59
218	Lenalidomide: an update on evidence from clinical trials. <i>Blood Reviews</i> , 2010 , 24 Suppl 1, S21-6	11.1	8
217	High Circulating Levels of Sclerostin Correlate with Bone Mineral Density In Patients with Thalassemia and Osteoporosis: The Role of the Wnt Signaling In the Pathogenesis of Bone Loss In Thalassemia. <i>Blood</i> , 2010 , 116, 1010-1010	2.2	2
216	Liver Transient Elastography (FibroScan) Correlates with Liver Iron Concentration and Reflects Liver Fibrosis In Patients with Sickle Cell Disease. <i>Blood</i> , 2010 , 116, 1646-1646	2.2	4
215	Circulating Levels of the Wnt Inhibitors Dickkopf-1 and Sclerostin In Different Phases of Multiple Myeloma: Alterations Post-Therapy with Lenalidomide and Dexamethasone with or without Bortezomib. <i>Blood</i> , 2010 , 116, 2963-2963	2.2	7
214	Elevated Levels of Circulating Activin-A Correlate with Features of Advanced Disease, Extensive Bone Involvement and Inferior Survival In Patients with Multiple Myeloma. <i>Blood</i> , 2010 , 116, 2967-2967	2.2	4
213	Elevated Serum Lactate Dehydrogenase (LDH) Should Be Included Among the Variables Which Define High Risk Multiple myeloma. <i>Blood</i> , 2010 , 116, 2969-2969	2.2	1
212	Renal Impairment Is Not An Independent Adverse Prognostic Factor In Multiple Myeloma Patients Who Are Treated Upfront with Novel Agent-Based Regimens. <i>Blood</i> , 2010 , 116, 3033-3033	2.2	1
211	The Combination of the Proteasome Inhibitor Bortezomib with Doxorubicin and Dexamethasone (PAD Regimen) as Front-Line Therapy In Newly Diagnosed, High-Risk Multiple Myeloma: Results of a Phase II Prospective Multicenter Study. <i>Blood</i> , 2010 , 116, 3052-3052	2.2	2
210	Low Bone Mineral Density and High Bone Turnover In Patients with Non-Hodgkin's Lymphoma (NHL) Who Receive Frontline Therapy: Results of a Multicenter Prospective Study. <i>Blood</i> , 2010 , 116, 5071-5071 ¹	2.2	1
209	Biochemical Markers of Bone Remodeling in Multiple Myeloma 2010 , 63-89		
208	Long Term Follow up of the Combination of Bortezomib with Dexamethasone as Initial Treatment for AL Amyloidosis. <i>Blood</i> , 2010 , 116, 3048-3048	2.2	
207	Over-Expression of RANKL In Invariant NKT Cells Is Characteristic of Active Myeloma but Not of MGUS or Asymptomatic Myeloma. <i>Blood</i> , 2010 , 116, 4049-4049	2.2	
206	Primary Therapy of Waldenstrom's Macroglobulinemia (WM) with Weekly Bortezomib, Low-Dose Dexamethasone and Rituximab (BDR): A Phase II Study of the European Myeloma Network. <i>Blood</i> , 2010 , 116, 1941-1941	2.2	3
205	Upfront Treatment with Novel Agents Improves the Survival of Symptomatic Patients with Multiple Myeloma Who Are Older Than 65 Years. <i>Blood</i> , 2010 , 116, 1947-1947	2.2	

204	Increased Expression of Cyclin-D1 on Trephine Bone Marrow Biopsies Independently Predicts for Shorter Overall Survival In Patients with Multiple Myeloma Treated with Novel Agents. <i>Blood</i> , 2010 , 116, 2965-2965	2.2	
203	Reduced Repair Efficiency Correlates with Increased Cellular Chemosensitivity and Better Response to High Dose Melphalan of Patients with Multiple Myeloma. <i>Blood</i> , 2010 , 116, 2976-2976	2.2	
202	Short Progression Free Survival Predicts for Poor Overall Survival In Older Patients with Multiple Myeloma Treated Upfront with Novel Agent-Based Therapy. <i>Blood</i> , 2010 , 116, 3035-3035	2.2	
201	Differences In DNA Damage Response Pathways In the PBMCs of Patients with MGUS, Asymptomatic Myeloma and Symptomatic Multiple Myeloma. <i>Blood</i> , 2010 , 116, 2974-2974	2.2	
200	The International Scoring System (ISS) for Multiple Myeloma Remains a Robust Prognostic Tool Independently of Patients' Renal Function. <i>Blood</i> , 2010 , 116, 3036-3036	2.2	
199	Serum Dickkopf-1 is increased and correlates with reduced bone mineral density in patients with thalassemia-induced osteoporosis. Reduction post-zoledronic acid administration. <i>Haematologica</i> , 2009 , 94, 725-728	6.6	41
198	RANKL inhibition: clinical implications for the management of patients with multiple myeloma and solid tumors with bone metastases. <i>Expert Opinion on Biological Therapy</i> , 2009 , 9, 465-79	5.4	25
197	Pathogenesis and management of myeloma bone disease. <i>Expert Review of Hematology</i> , 2009 , 2, 385-98	2.8	40
196	Hematology: first-line bortezomib benefits patients with multiple myeloma. <i>Nature Reviews Clinical Oncology</i> , 2009 , 6, 683-5	19.4	6
195	The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. <i>Annals of Oncology</i> , 2009 , 20, 1303-17	10.3	171
194	Effect of strontium ranelate on lumbar spine bone mineral density in women with established osteoporosis previously treated with teriparatide. <i>Hormone and Metabolic Research</i> , 2009 , 41, 559-62	3.1	9
193	The effect of zoledronic acid on serum dickkopf-1, osteoprotegerin, and RANKL in patients with Paget's disease of bone. <i>Hormone and Metabolic Research</i> , 2009 , 41, 846-50	3.1	21
192	Efficacy and safety of denosumab in postmenopausal women with osteopenia or osteoporosis: a systematic review and a meta-analysis. <i>Hormone and Metabolic Research</i> , 2009 , 41, 721-9	3.1	79
191	Applications of monoclonal antibodies for the treatment of hematological malignancies. <i>Expert Opinion on Biological Therapy</i> , 2009 , 9, 207-20	5.4	14
190	Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration. <i>Haematologica</i> , 2009 , 94, 372-9	6.6	55
189	Sequential evaluation of serum hepcidin in anemic myeloma patients: study of correlations with myeloma treatment, disease variables, and anemia response. <i>American Journal of Hematology</i> , 2009 , 84, 524-6	7.1	14
188	Curcumin diminishes human osteoclastogenesis by inhibition of the signalosome-associated I kappaB kinase. <i>Journal of Cancer Research and Clinical Oncology</i> , 2009 , 135, 173-9	4.9	39
187	Transient secondary hyperparathyroidism following intravenous infusion of zoledronic acid. <i>Supportive Care in Cancer</i> , 2009 , 17, 1329-30	3.9	12

186	Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG). <i>Leukemia</i> , 2009 , 23, 1152-7	10.7	165
185	Increased expression of macrophage inflammatory protein-1alpha on trephine biopsies correlates with extensive bone disease, increased angiogenesis and advanced stage in newly diagnosed patients with multiple myeloma. <i>Leukemia</i> , 2009 , 23, 2177-81	10.7	50
184	International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma. <i>Leukemia</i> , 2009 , 23, 1545-56	10.7	356
183	Update on the use of erythropoiesis-stimulating agents (ESAs) for the management of anemia of multiple myeloma and lymphoma. <i>Cancer Treatment Reviews</i> , 2009 , 35, 738-43	14.4	8
182	Paget's disease of bone: emphasis on treatment with zoledronic acid. <i>Expert Review of Endocrinology and Metabolism</i> , 2009 , 4, 423-434	4.1	9
181	Angiogenesis in Waldenström's macroglobulinemia. <i>Clinical Lymphoma and Myeloma</i> , 2009 , 9, 46-9		9
180	Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors. <i>Clinical Lymphoma and Myeloma</i> , 2009 , 9, 302-6		85
179	Serum levels of total-RANKL in multiple myeloma. <i>Clinical Lymphoma and Myeloma</i> , 2009 , 9, 430-5		22
178	Dickkopf-1: a suitable target for the management of myeloma bone disease. <i>Expert Opinion on Therapeutic Targets</i> , 2009 , 13, 839-48	6.4	56
177	RANKL inhibition for the management of patients with benign metabolic bone disorders. <i>Expert Opinion on Investigational Drugs</i> , 2009 , 18, 1085-102	5.9	23
176	Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. <i>Annals of Oncology</i> , 2009 , 20, 117-20	10.3	294
175	Novel Anti-Myeloma Agents and Bone Metabolism: Implications in the Management of Myeloma Bone Disease. <i>Clinical Lymphoma and Myeloma</i> , 2009 , 9, S30-S32		
174	Management of complications in multiple myeloma. <i>Seminars in Hematology</i> , 2009 , 46, 176-89	4	22
173	Regulation of multiple myeloma survival and progression by CD1d. <i>Blood</i> , 2009 , 113, 2498-507	2.2	71
172	The Addition of Bortezomib to the Combination of Lenalidomide and Dexamethasone Increases Bone Formation in Relapsed/Refractory Myeloma: a Prospective Study in 91 Patients.. <i>Blood</i> , 2009 , 114, 1815-1815	2.2	3
171	First-Line Chemotherapy Leads to High Bone Turnover and Reduced Bone Mass in Patients with Non-Hodgkin's Lymphoma (NHL).. <i>Blood</i> , 2009 , 114, 1951-1951	2.2	1
170	Consolidation Therapy with Bortezomib, Thalidomide and Dexamethasone (VTD) Regimen After ASCT in Myeloma Patients Who Do Not Receive Bisphosphonates Reduces Bone Resorption and RANKL/OPG Ratio but Seems to Have No Effect On Bone Formation and Angiogenesis.. <i>Blood</i> , 2009 , 114, 3863-3863	2.2	2
169	Hyperphosphorylated Paratarg-7 Is a Frequent Antigenic Target of IgM Paraproteins, Is Dominantly Inherited and Represents a Highly Significant Risk Factor for Monoclonal Gammopathy of Undetermined Significance of the IgM Type (IgM-MGUS) and Waldenström's Macroglobulinemia (WM).. <i>Blood</i> , 2009 , 114, 3935-3935	2.2	1

168	High Serum Sclerostin Correlates with Advanced Stage, Increased Bone Resorption, Reduced Osteoblast Function, and Poor Survival in Newly-Diagnosed Patients with Multiple Myeloma.. <i>Blood</i> , 2009 , 114, 425-425	2.2	4
167	A Phase I/II Study of Lenalidomide (R) with Low Dose Dexamethasone (d) and Cyclophosphamide (C) for Patients with Primary Systemic (AL) Amyloidosis.. <i>Blood</i> , 2009 , 114, 428-428	2.2	2
166	Reversibility of Renal Failure in Newly Diagnosed Patients with Multiple Myeloma and the Role of Novel Agents.. <i>Blood</i> , 2009 , 114, 955-955	2.2	1
165	Treatment of Patients with Relapsed/Refractory Multiple Myeloma (MM) with Lenalidomide and Dexamethasone with or without Bortezomib: Prospective Evaluation of the Impact of Cytogenetic Abnormalities.. <i>Blood</i> , 2009 , 114, 958-958	2.2	3
164	Serum Dickkopf-1 is increased and correlates with reduced bone mineral density in patients with thalassemia-induced osteoporosis. Reduction post-zoledronic acid administration. <i>Haematologica</i> , 2009 , 94, 725-8	6.6	18
163	Correlation of Erythropoietin Stimulating Agents (ESAs) with the Post-Therapy Micro-Vessel Density (MVD) in Newly Diagnosed Myeloma Patients: a Possible Mechanism of ESAs Association with Reduced Survival Rates.. <i>Blood</i> , 2009 , 114, 4873-4873	2.2	
162	Increased levels of Vascular Cell Adhesion Molecule-1 (VCAM-1) and Inter-Cellular Adhesion Molecule-1 (ICAM-1) Correlate with Advanced Disease Features and Poor Survival in Newly Diagnosed Patients with Multiple Myeloma. Reduction Post-Bortezomib- and Lenalidomide-Based Regimens.. <i>Blood</i> , 2009 , 114, 1824-1824	2.2	
161	Antibacterial Prophylaxis Reduces the Incidence of Neutropenic Fever and the Rate of Infections in Patients with Multiple Myeloma Who Undergo An Autologous Stem Cell Transplantation.. <i>Blood</i> , 2009 , 114, 3334-3334	2.2	
160	Angiogenic Molecules and Inflammatory Cytokines in Patients with Thalassemia Major and Double Heterozygous HbS/Beta-Thalassemia; the impact of Deferasirox.. <i>Blood</i> , 2009 , 114, 2018-2018	2.2	
159	High Serum Lactate Dehydrogenase (LDH) Is An Important Prognostic Factor in the Era of Novel Agents and Adds to the Prognostic Value of the International Staging System (ISS) in Patients with Multiple Myeloma.. <i>Blood</i> , 2009 , 114, 1819-1819	2.2	
158	Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom's Macroglobulinemia (WM) and the Importance of Serum Lactate Dehydrogenase (LDH).. <i>Blood</i> , 2009 , 114, 2845-2845	2.2	
157	The Impact of Different Pre-Transplant Regimens Including Novel Agents On Peripheral Blood Mobilization, Harvest, Response and Survival in Patients Undergoing ASCT for Multiple Myeloma. A Single-Center Experience in 210 Patients.. <i>Blood</i> , 2009 , 114, 2279-2279	2.2	
156	Lenalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma; Dosing of Lenalidomide According to Renal Function and Effect On Renal Impairment.. <i>Blood</i> , 2009 , 114, 3871-3871	2.2	
155	Treatment with Deferasirox Effectively Decreases Iron Burden in Patients with Sickle Cell Disease and Thalassemia Intermedia.. <i>Blood</i> , 2009 , 114, 1517-1517	2.2	
154	Alterations in the Epigenetic Network Controlling Transcription Activity, Chromatin Structure and Region-Specific Repair of Different Genomic Loci Predicts Clinical Outcome in Multiple Myeloma.. <i>Blood</i> , 2009 , 114, 122-122	2.2	
153	Primary Treatment of Waldenstrom's Macroglobulinemia with Dexamethasone, Rituximab and Cyclophosphamide (DRC): Long Term Follow-up Analysis of a Phase II Study.. <i>Blood</i> , 2009 , 114, 2887-2887	2.2	0
152	A Polymerase Chain Reaction-Based Method to Detect Gene-Specific Adducts Induced by Anticancer Drugs. Clinical Application in Multiple Myeloma.. <i>Blood</i> , 2009 , 114, 1879-1879	2.2	
151	Diffuse MRI Marrow Pattern Correlates with Increased Angiogenesis, Advanced Disease Features and Poor Prognosis in Newly-Diagnosed Patients with Multiple Myeloma Treated with Novel Agents.. <i>Blood</i> , 2009 , 114, 829-829	2.2	

150	Primary Therapy of Waldenström's Macroglobulinemia (WM) with Weekly Bortezomib, Low-Dose Dexamethasone and Rituximab (BDR): A Phase II Study of the European Myeloma Network.. <i>Blood</i> , 2009 , 114, 2886-2886	2.2	
149	The clinical significance of serum markers of bone turnover in NSCLC patients: surveillance, management and prognostic implications. <i>Anticancer Research</i> , 2009 , 29, 1651-7	2.3	28
148	The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis. <i>Leukemia</i> , 2008 , 22, 2247-56	10.7	106
147	Reply to Proteasome inhibition therapies in childhood cancer by Zaman et al.. <i>Leukemia</i> , 2008 , 22, 884-885.	5.7	1
146	Increased CD177 (PRV1) expression in thalassaemia and the underlying erythropoietic activity. <i>British Journal of Haematology</i> , 2008 , 141, 100-4	4.5	6
145	Use of erythropoiesis stimulating agents and intravenous iron for cancer and treatment-related anaemia: the need for predictors and indicators of effectiveness has not abated. <i>British Journal of Haematology</i> , 2008 , 142, 3-10	4.5	13
144	Prevalence and significance of vitamin D deficiency in multiple myeloma patients. <i>British Journal of Haematology</i> , 2008 , 142, 492-4	4.5	56
143	Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy. <i>Gynecologic Oncology</i> , 2008 , 108, 421-7	4.9	71
142	The potential of proteasome inhibitors in cancer therapy. <i>Expert Opinion on Investigational Drugs</i> , 2008 , 17, 879-95	5.9	102
141	Aurora kinases as targets for cancer therapy. <i>Cancer Treatment Reviews</i> , 2008 , 34, 175-82	14.4	115
140	Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions. <i>Cancer Treatment Reviews</i> , 2008 , 34, 629-39	14.4	103
139	Antibodies to receptor activator of nuclear factor- κ B ligand (RANKL). <i>Expert Opinion on Therapeutic Patents</i> , 2008 , 18, 1265-1269	6.8	2
138	Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens. <i>Leukemia and Lymphoma</i> , 2008 , 49, 890-5	1.9	65
137	Continuous increase in erythropoietic activity despite the improvement in bone mineral density by zoledronic acid in patients with thalassemia intermedia-induced osteoporosis. <i>Acta Haematologica</i> , 2008 , 119, 40-4	2.7	12
136	Pegylated interferon plus ribavirin combination therapy for chronic hepatitis C in patients with congenital coagulation disorders. <i>Acta Haematologica</i> , 2008 , 120, 63-9	2.7	6
135	Bortezomib in multiple myeloma. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2008 , 4, 639-54	5.5	16
134	Natural history of osteonecrosis of the jaw in patients with multiple myeloma. <i>Journal of Clinical Oncology</i> , 2008 , 26, 5904-9	2.2	124
133	Novel anti-myeloma agents and angiogenesis. <i>Leukemia and Lymphoma</i> , 2008 , 49, 677-89	1.9	35

132	Continuous improvement of bone mineral density two years post zoledronic acid discontinuation in patients with thalassemia-induced osteoporosis: long-term follow-up of a randomized, placebo-controlled trial. <i>Haematologica</i> , 2008 , 93, 1588-90	6.6	25
131	Normalization of the serum angiopoietin-1 to angiopoietin-2 ratio reflects response in refractory/resistant multiple myeloma patients treated with bortezomib. <i>Haematologica</i> , 2008 , 93, 451-4	6.6	25
130	Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. <i>Cancer</i> , 2008 , 113, 193-201	6.4	226
129	Erythropoiesis-stimulating agents are associated with reduced survival in patients with multiple myeloma. <i>American Journal of Hematology</i> , 2008 , 83, 697-701	7.1	32
128	Have myeloma cells osteoclast-like activity? Implications into the pathogenesis of myeloma bone disease. <i>Leukemia Research</i> , 2008 , 32, 521-2	2.7	1
127	Response of primary plasma cell leukemia to the combination of bortezomib and dexamethasone: do specific cytogenetic and immunophenotypic characteristics influence treatment outcome?. <i>Leukemia Research</i> , 2008 , 32, 1153-6	2.7	32
126	High levels of synovial fluid osteoprotegerin (OPG) and increased serum ratio of receptor activator of nuclear factor-kappa B ligand (RANKL) to OPG correlate with disease severity in patients with primary knee osteoarthritis. <i>Clinical Biochemistry</i> , 2008 , 41, 746-9	3.5	50
125	Prolonged Administration of Hydroxyurea Reduces Morbidity and Mortality in Adult Patients with Sickle-Cell Syndromes: Long-Term Experience of a Single Center.. <i>Blood</i> , 2008 , 112, 1445-1445	2.2	2
124	Reversibility of Renal Impairment of Multiple Myeloma Patients Treated with Bortezomib-Based Regimens: Identification of Predictive Factors.. <i>Blood</i> , 2008 , 112, 1725-1725	2.2	1
123	Deferasirox Reduces Serum TNF- α but Impairs Renal Function in Patients with Thalassemia Major after 12 Months of Therapy. <i>Blood</i> , 2008 , 112, 3888-3888	2.2	1
122	Serum Dickkopf-1 Is Increased and Correlates with Bone Mineral Density in Patients with Thalassemia-Induced Osteoporosis. Reduction Post Zoledronic Acid Administration. <i>Blood</i> , 2008 , 112, 3889-3889	2.2	1
121	Increased Levels of Serum Tissue Inhibitor of Metalloproteinase-1 Correlate with Advanced Stage, Increased Bone Resorption, Lytic Bone Disease and Poor Survival in Newly-Diagnosed Myeloma Patients. <i>Blood</i> , 2008 , 112, 5143-5143	2.2	
120	Osteopontin Predicts for Survival and Cystatin C-Based Estimated GFR Predicts for Renal Response to Therapy in Patients with Primary Systemic Amyloidosis. <i>Blood</i> , 2008 , 112, 2731-2731	2.2	
119	Regulation of Multiple Myeloma Survival and Progression by CD1d. <i>Blood</i> , 2008 , 112, 2720-2720	2.2	
118	Strong Correlation Between Angiogenesis and Macrophage Counts in Waldenstrom's Macroglobulinemia: Implications into the Biology of the Disease. <i>Blood</i> , 2008 , 112, 5108-5108	2.2	
117	Improved Survival of Patients with Multiple Myeloma after the Introduction of Novel Agents and the Applicability of the International Staging System (ISS) An Analysis of the Greek Myeloma Study Group (GMSG). <i>Blood</i> , 2008 , 112, 655-655	2.2	
116	Immunoexpression of Macrophage Inflammatory Protein-1 Alpha on Bone Marrow Trepine Biopsies Correlates with the Extent of Bone Disease in Newly Diagnosed Patients with Multiple Myeloma. <i>Blood</i> , 2008 , 112, 5119-5119	2.2	
115	The Administration of Bortezomib, Dexamethasone and Thalidomide (VTD) after ASCT in Myeloma Patients Who Do Not Receive Bisphosphonates Normalizes sRANKL, Dickkopf-1 and Improves Abnormal Osteoclast Function and Impaired Angiogenesis.. <i>Blood</i> , 2008 , 112, 1728-1728	2.2	

114	Treatment of Patients with Relapsed/Refractory Multiple Myeloma (MM) with Lenalidomide and Dexamethasone with or with Bortezomib Depending on Prior Neurotoxicity: Prospective Evaluation of the Impact of Cytogenetic Abnormalities and Assessment of Bone Met.. <i>Blood</i> , 2008 , 112, 1726-1726	2.2	
113	Increased Plasma Levels of NGAL and IL-18 Correlate with Reduced GFR Providing Two Novel Biomarkers for Kidney Injury Assessment: Evidence of Early Tubuloglomerular Defect in Patients with HbS/b-Thalassemia. <i>Blood</i> , 2008 , 112, 4805-4805	2.2	
112	Reduction of CD55 and/or CD59 in red blood cells of patients with HIV infection. <i>Medical Science Monitor</i> , 2008 , 14, CR276-280	3.2	14
111	Interactions between osteoclasts, osteoblasts and immune cells: implications for the pathogenesis of bone loss in thalassemia. <i>Pediatric Endocrinology Reviews</i> , 2008 , 6 Suppl 1, 94-106	1.1	4
110	Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton. <i>Acta Oncologica</i> , 2007 , 46, 221-9	3.2	73
109	Clinical utility of biochemical markers of bone metabolism for improving the management of patients with advanced multiple myeloma. <i>Clinical Lymphoma and Myeloma</i> , 2007 , 7, 346-53		22
108	Bortezomib is an effective agent for MDS/MPD syndrome with 5q- anomaly and thrombocytosis. <i>Leukemia Research</i> , 2007 , 31, 559-62	2.7	24
107	The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma. <i>Leukemia</i> , 2007 , 21, 1875-84	10.7	75
106	Serum concentrations of angiogenic cytokines in Waldenstrom macroglobulinaemia: the ration of angiopoietin-1 to angiopoietin-2 and angiogenin correlate with disease severity. <i>British Journal of Haematology</i> , 2007 , 137, 560-8	4.5	33
105	Hypochromic erythrocytes (%): a reliable marker for recognizing iron-restricted erythropoiesis and predicting response to erythropoietin in anemic patients with myeloma and lymphoma. <i>Annals of Hematology</i> , 2007 , 86, 369-76	3	22
104	Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. <i>Journal of Clinical Oncology</i> , 2007 , 25, 3344-9	2.2	189
103	Myeloma bone disease and proteasome inhibition therapies. <i>Blood</i> , 2007 , 110, 1098-104	2.2	120
102	VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: results of a multicenter randomized trial of the Greek Myeloma Study Group. <i>Annals of Oncology</i> , 2007 , 18, 1369-75	10.3	51
101	Successful treatment of extramedullary plasmacytoma of the cavernous sinus using a combination of intermediate dose of thalidomide and dexamethasone. <i>Acta Haematologica</i> , 2007 , 117, 20-3	2.7	12
100	Pulmonary hypertension in patients with sickle cell/beta thalassemia: incidence and correlation with serum N-terminal pro-brain natriuretic peptide concentrations. <i>Haematologica</i> , 2007 , 92, 738-43	6.6	51
99	Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone. <i>Haematologica</i> , 2007 , 92, 1351-8	6.6	157
98	Cystatin-C Is a Sensitive Marker of Renal Impairment with an Independent Predictive Value for Survival in Multiple Myeloma; Reduction Post Bortezomib Monotherapy.. <i>Blood</i> , 2007 , 110, 1484-1484	2.2	5
97	Treatment of Light Chain (AL) Amyloidosis and Light Chain Deposition Disease (LCDD) with the Combination of Bortezomib and Dexamethasone.. <i>Blood</i> , 2007 , 110, 191-191	2.2	1

96	Treatment of Patients with Multiple Myeloma Complicated by Renal Failure with Bortezomib - Based Regimens.. <i>Blood</i> , 2007 , 110, 2739-2739	2.2	2
95	The Combination of Bortezomib, Doxorubicin, and Dexamethasone (PAD) Is an Effective Regimen for High Risk, Newly Diagnosed, Patients with Multiple Myeloma, Reduces Bone Resorption and Normalizes Angiopoietin-1 to Angiopoietin-2 Ratio.. <i>Blood</i> , 2007 , 110, 3596-3596	2.2	2
94	Zoledronic Acid Increases Bone Mineral Density in Patients with Thalassemia Intermedia-Induced Osteoporosis Regardless of the Incessant Bone Marrow Expansion.. <i>Blood</i> , 2007 , 110, 3813-3813	2.2	1
93	Increased Bone Resorption Is Implicated in the Pathogenesis of Bone Loss in Hemophilia Patients: Correlations with Severity of Hemophilic Arthropathy and HIV Infection.. <i>Blood</i> , 2007 , 110, 493-493	2.2	1
92	Bone Remodeling in Patients with Relapsed/Refractory Multiple Myeloma Who Receive Lenalidomide-Based Regimens.. <i>Blood</i> , 2007 , 110, 4745-4745	2.2	
91	Increased Levels of Urinary N-Telopeptide of Type I Collagen Correlate with Reduced Survival in Patients with Advanced Multiple Myeloma.. <i>Blood</i> , 2007 , 110, 1499-1499	2.2	1
90	The International Prognostic Scoring System for Waldstrom's Macroglobulinemia (ISSWM) Is Applicable in Patients Treated with Rituximab-Based Regimens.. <i>Blood</i> , 2007 , 110, 3615-3615	2.2	
89	Predictors for Skeletal-Related Events in Patients with Advanced Multiple Myeloma.. <i>Blood</i> , 2007 , 110, 1482-1482	2.2	1
88	The Bone Resorption Marker Serum-ICTP and the Circulating Proteasome Levels Separate ISS-Stages 1B and Are the Most Powerful Prognostic Factors for Overall Survival in Newly Diagnosed Symptomatic Multiple Myeloma.. <i>Blood</i> , 2007 , 110, 1475-1475	2.2	
87	High Serum Levels of Angiogenic Cytokines in AL Amyloidosis Correlates with Disease Features.. <i>Blood</i> , 2007 , 110, 4781-4781	2.2	
86	The Addition of sFLCR Improves ISS Prognostication in Multiple Myeloma (MM).. <i>Blood</i> , 2007 , 110, 1490-1490	2.2	1
85	The Ratio of Angiopoietin-1 to Angiopoietin-2 Is Reduced and Predicts Independently for Survival in Newly Diagnosed Patients with Multiple Myeloma.. <i>Blood</i> , 2007 , 110, 1478-1478	2.2	
84	Symptomatic Waldenstrom's Macroglobulinemia (WM) in Young Patients: Disease Characteristics and Outcome.. <i>Blood</i> , 2007 , 110, 4730-4730	2.2	
83	Continuous Improvement of Bone Mineral Density Two Years Post Zoledronic Acid Discontinuation in Patients with Thalassemia-Induced Osteoporosis: Long-Term Follow-Up of a Randomized, Placebo-Controlled Trial.. <i>Blood</i> , 2007 , 110, 2768-2768	2.2	
82	High Bone Turnover and Increased Angiogenesis Cytokines in Patients with POEMS Syndrome.. <i>Blood</i> , 2007 , 110, 3525-3525	2.2	
81	Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation. <i>International Journal of Cancer</i> , 2006 , 119, 1728-31	7.5	139
80	Macrofocal multiple myeloma in young patients: a distinct entity with favorable prognosis. <i>Leukemia and Lymphoma</i> , 2006 , 47, 1553-6	1.9	24
79	Clinical implications of chromosomal abnormalities in multiple myeloma. <i>Leukemia and Lymphoma</i> , 2006 , 47, 803-14	1.9	29

78	Biochemical markers of bone metabolism in multiple myeloma. <i>Cancer Treatment Reviews</i> , 2006 , 32 Suppl 1, 15-9	14.4	33
77	Antibodies to dickkopf-1 protein. <i>Expert Opinion on Therapeutic Patents</i> , 2006 , 16, 1453-1458	6.8	2
76	Abnormal bone remodelling and increased levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) in Waldenström macroglobulinaemia. <i>British Journal of Haematology</i> , 2006 , 133, 301-4	4.5	22
75	Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. <i>British Journal of Haematology</i> , 2006 , 134, 620-3	4.5	223
74	Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. <i>British Journal of Haematology</i> , 2006 , 135, 688-92	4.5	197
73	Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients. <i>Bone Marrow Transplantation</i> , 2006 , 37, 731-4	4.4	83
72	Early markers of renal dysfunction in patients with sickle cell/beta-thalassemia. <i>Kidney International</i> , 2006 , 69, 2037-42	9.9	48
71	The Combination of Bortezomib, Melphalan, Dexamethasone and Intermittent Thalidomide (VMDT) Is an Effective Regimen for Relapsed/Refractory Myeloma and Reduces Serum Levels of Dickkopf-1, RANKL, MIP-1 and Angiogenic Cytokines.. <i>Blood</i> , 2006 , 108, 3541-3541	2.2	7
70	Bortezomib Reduces Serum Dickkopf-1 and RANKL Concentrations and Normalizes Indices of Bone Remodeling in Patients with Relapsed Multiple Myeloma.. <i>Blood</i> , 2006 , 108, 506-506	2.2	1
69	VAD-doxil vs.VAD-doxil Plus Thalidomide as Initial Treatment in Patients with Multiple Myeloma: A Multicenter Randomized Trial of the Greek Myeloma Study Group.. <i>Blood</i> , 2006 , 108, 794-794	2.2	3
68	The Serum Levels of N-Terminal Pro B-Type Natriuretic Peptide (NT-proBNP) Is a Strong Indicator of Pulmonary Hypertension in Patients with Sickle Cell/Beta Thalassemia.. <i>Blood</i> , 2006 , 108, 1207-1207	2.2	
67	Melphalan-Induced DNA Damage In Vitro as Predictor for Clinical Outcome in Multiple Myeloma.. <i>Blood</i> , 2006 , 108, 60-60	2.2	
66	Primary treatment with pulsed melphalan, dexamethasone and thalidomide for elderly symptomatic patients with multiple myeloma. <i>Haematologica</i> , 2006 , 91, 252-4	6.6	32
65	Osteoporosis and osteosclerosis in sickle cell/beta-thalassemia: the role of the RANKL/osteoprotegerin axis. <i>Haematologica</i> , 2006 , 91, 813-6	6.6	30
64	Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. <i>Haematologica</i> , 2006 , 91, 968-71	6.6	202
63	Novel agents for the management of myelodysplastic syndromes. <i>Medical Science Monitor</i> , 2006 , 12, RA194-206	3.2	3
62	Zoledronic acid for the treatment of osteoporosis in patients with beta-thalassemia: results from a single-center, randomized, placebo-controlled trial. <i>Haematologica</i> , 2006 , 91, 1193-202	6.6	49
61	Current treatment options for myeloma. <i>Expert Opinion on Pharmacotherapy</i> , 2005 , 6, 1127-42	4	9

60	Significance of macrophage inflammatory protein-1 alpha (MIP-1alpha) in multiple myeloma. <i>Leukemia and Lymphoma</i> , 2005 , 46, 1699-707	1.9	60
59	Myeloma bone disease: pathophysiology and management. <i>Annals of Oncology</i> , 2005 , 16, 1223-31	10.3	155
58	The role of markers of bone remodeling in multiple myeloma. <i>Blood Reviews</i> , 2005 , 19, 125-42	11.1	39
57	The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio. <i>Leukemia</i> , 2005 , 19, 1969-76	10.7	90
56	Osteoprotegerin to soluble receptor activator of nuclear factor kappa-B ligand ratio is reduced in patients with thalassaemia-related osteoporosis who receive vitamin D3. <i>European Journal of Haematology</i> , 2005 , 74, 359-61	3.8	16
55	Macrophage Inflammatory Protein-1 alpha (MIP-1alpha) is over-expressed in a cohort of patients with myelodysplastic syndromes. <i>European Journal of Haematology</i> , 2005 , 75, 85-6	3.8	5
54	Plasmacytoma relapses in the absence of systemic progression post-high-dose therapy for multiple myeloma. <i>European Journal of Haematology</i> , 2005 , 75, 376-83	3.8	53
53	Deferiprone as an oral iron chelator in sickle cell disease. <i>Annals of Hematology</i> , 2005 , 84, 434-40	3	34
52	Anti-angiogenic effect of bortezomib in patients with multiple myeloma. <i>Acta Haematologica</i> , 2005 , 114, 170-3	2.7	26
51	The Combination of Bortezomib, Melphalan, Dexamethasone and Intermittent Thalidomide (VMDT) Is an Effective Treatment for Relapsed/Refractory Myeloma: Results of a Phase II Clinical Trial.. <i>Blood</i> , 2005 , 106, 363-363	2.2	10
50	Zoledronic Acid Is an Effective Treatment for Osteoporosis in Patients with Thalassemia Major: Results of a Randomized, Placebo-Controlled, Trial.. <i>Blood</i> , 2005 , 106, 3656-3656	2.2	1
49	Autoimmune hemolytic anemia with myelodysplastic features followed by bilateral adrenal non-hodgkin lymphoma: a case report and review of the literature. <i>Leukemia and Lymphoma</i> , 2004 , 45, 2333-8	1.9	8
48	Bisphosphonate treatment for the management of osteoporosis in beta-thalassaemia. <i>British Journal of Haematology</i> , 2004 , 125, 93-94	4.5	3
47	Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS). <i>British Journal of Haematology</i> , 2004 , 126, 686-9	4.5	80
46	Magnetic resonance imaging in the evaluation of iron overload in patients with beta thalassaemia and sickle cell disease. <i>British Journal of Haematology</i> , 2004 , 126, 736-42	4.5	116
45	New insights into the pathophysiology and management of osteoporosis in patients with beta thalassaemia. <i>British Journal of Haematology</i> , 2004 , 127, 127-39	4.5	143
44	Autologous stem cell transplantation normalizes abnormal bone remodeling and sRANKL/osteoprotegerin ratio in patients with multiple myeloma. <i>Leukemia</i> , 2004 , 18, 1420-6	10.7	59
43	Tumour lysis syndrome in multiple myeloma after bortezomib (VELCADE) administration. <i>Journal of Cancer Research and Clinical Oncology</i> , 2004 , 130, 623-5	4.9	34

42	The combination of intermediate doses of thalidomide and dexamethasone reduces bone marrow micro-vessel density but not serum levels of angiogenic cytokines in patients with refractory/relapsed multiple myeloma. <i>Hematological Oncology</i> , 2004 , 22, 159-68	1.3	25
41	Primary Treatment with Pulsed Melphalan, Dexamethasone, Thalidomide (MDT) for Symptomatic Patients with Multiple Myeloma \geq 5 Years of Age.. <i>Blood</i> , 2004 , 104, 1482-1482	2.2	4
40	Bisphosphonate treatment for multiple myeloma. <i>Drugs of Today</i> , 2004 , 40, 29-40		25
39	Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myeloma. <i>Annals of Oncology</i> , 2003 , 14, 1039-44	10.3	57
38	Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. <i>Blood</i> , 2003 , 102, 1064-9	2.2	348
37	Unusual association between increased bone resorption and presence of paroxysmal nocturnal hemoglobinuria phenotype in multiple myeloma. <i>International Journal of Hematology</i> , 2003 , 78, 344-8	2.3	7
36	Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and beta 2-microglobulin in multiple myeloma. <i>European Journal of Haematology</i> , 2003 , 70, 34-42	3.8	40
35	Reply - Is ibandronate effective in multiple myeloma?. <i>European Journal of Haematology</i> , 2003 , 71, 471-472		3
34	Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma. <i>International Journal of Cancer</i> , 2003 , 106, 455-7	7.5	76
33	Serum levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) correlate with the extent of bone disease and survival in patients with multiple myeloma. <i>British Journal of Haematology</i> , 2003 , 123, 106-9	4.5	137
32	Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia. <i>British Journal of Haematology</i> , 2003 , 123, 730-7	4.5	73
31	New insights into the pathophysiology and management of bone disease in multiple myeloma. <i>British Journal of Haematology</i> , 2003 , 123, 758-69	4.5	41
30	Disseminated <i>Aspergillus terreus</i> infection arising from cutaneous inoculation treated with caspofungin. <i>Clinical Microbiology and Infection</i> , 2003 , 9, 1238-41	9.5	13
29	Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients. <i>Bone Marrow Transplantation</i> , 2003 , 31, 163-70	4.4	51
28	Clinicopathologic correlations of bone marrow angiogenesis in chronic myeloid leukemia: a morphometric study. <i>Leukemia</i> , 2003 , 17, 89-97	10.7	60
27	Recent insights into the pathophysiology of paroxysmal nocturnal hemoglobinuria. <i>Medical Science Monitor</i> , 2003 , 9, RA161-72	3.2	18
26	Detection of CD55- and/or CD59-deficient red cell populations in patients with plasma cell dyscrasias. <i>International Journal of Hematology</i> , 2002 , 75, 40-4	2.3	18
25	Leukemogenic risk of hydroxyurea therapy as a single agent in polycythemia vera and essential thrombocythemia: N- and K-ras mutations and microsatellite instability in chromosomes 5 and 7 in 69 patients. <i>International Journal of Hematology</i> , 2002 , 75, 394-400	2.3	14

24	Treatment of anemia in low-risk myelodysplastic syndromes with amifostine. In vitro testing of response. <i>Annals of Hematology</i> , 2002 , 81, 182-6	3	5
23	Chronic myeloid leukaemia with marked thrombocytosis in a patient with thalassaemia major: complete haematological remission under the combination of hydroxyurea and anagrelide. <i>British Journal of Haematology</i> , 2002 , 116, 155-7	4.5	10
22	Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: a phase II trial in 281 patients. <i>British Journal of Haematology</i> , 2002 , 118, 174-80	4.5	90
21	Low dose melphalan is a treatment option in elderly patients with high risk myelodysplastic syndrome or secondary acute myeloblastic leukaemia. <i>Haematologia</i> , 2002 , 32, 169-73		8
20	Danazol therapy for thrombocytopenia in patients with myelodysplastic syndromes. <i>Acta Haematologica</i> , 2002 , 107, 234-6	2.7	5
19	Red cells with paroxysmal nocturnal hemoglobinuria-phenotype in patients with acute leukemia. <i>Hematology</i> , 2002 , 7, 69-74	2.2	10
18	Fetal Erythropoiesis after Allogeneic Bone Marrow Transplantation Estimated by the Peripheral Blood Erythrocytes Containing Hemoglobin F (F-cells). <i>Hematology</i> , 2001 , 5, 447-53	2.2	1
17	Pamidronate increases markers of bone formation in patients with multiple myeloma in plateau phase under interferon-alpha treatment. <i>Calcified Tissue International</i> , 2001 , 68, 285-90	3.9	18
16	Bone resorption is increased in young adults with thalassaemia major. <i>British Journal of Haematology</i> , 2001 , 112, 36-41	4.5	84
15	Behcet's disease in a patient with chronic myelogenous leukemia under hydroxyurea treatment: a case report and review of the literature. <i>American Journal of Hematology</i> , 2001 , 66, 57-8	7.1	16
14	Acute myeloid leukemia in a patient with ataxia-telangiectasia: a case report and review of the literature. <i>Leukemia</i> , 2001 , 15, 1668-70	10.7	18
13	Prognostic evaluation of the microvascular network in myelodysplastic syndromes. <i>Leukemia</i> , 2001 , 15, 1369-76	10.7	70
12	Myelodysplastic features in patients with long-term HIV infection and haemophilia. <i>Haemophilia</i> , 2001 , 7, 47-52	3.3	1
11	Detection of CD55 and/or CD59 deficient red cell populations in patients with aplastic anaemia, myelodysplastic syndromes and myeloproliferative disorders. <i>Haematologia</i> , 2001 , 31, 7-16		24
10	Detection of CD55- and/or CD59-deficient red cell populations in patients with lymphoproliferative syndromes. <i>The Hematology Journal</i> , 2001 , 2, 33-7		17
9	Myelodysplastic features in patients with long-term HIV infection and haemophilia. <i>Haemophilia</i> , 2001 , 7, 47-52	3.3	13
8	Effect of pamidronate administration on markers of bone turnover and disease activity in multiple myeloma. <i>European Journal of Haematology</i> , 2000 , 65, 331-6	3.8	58
7	Sjögren's syndrome associated with multiple myeloma. <i>Annals of Hematology</i> , 2000 , 79, 449-51	3	16

6	Hereditary hemochromatosis: HFE mutation analysis in Greeks reveals genetic heterogeneity. <i>Blood Cells, Molecules, and Diseases</i> , 2000 , 26, 163-8	2.1	33
5	Thrombophilic factors in patients with Syndrome X. <i>Thrombosis Research</i> , 2000 , 97, 525-7	8.2	
4	Inflammatory pseudotumor of the spleen: a case report and review of the literature. <i>Annals of Hematology</i> , 1999 , 78, 560-3	3	16
3	Severe aplastic anaemia relapsing during a pregnancy; spontaneous remission following termination. <i>Haematologia</i> , 1998 , 29, 147-51		3
2	Systemic lupus erythematosus presenting as myelofibrosis. <i>Haematologia</i> , 1998 , 29, 153-6		6
1	Detection of "PNH red cell" populations in hematological disorders using the Sephacryl Gel Test micro typing system. <i>Leukemia and Lymphoma</i> , 1997 , 28, 177-82	1.9	11